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ABSTRACT 
CAROLINE MARTZ LEE: Type 2B von Hippel-Lindau Disease: Molecular 
Biology, Tumor Growth, and Development 
(Under the direction of W. Kimryn Rathmell) 
 
Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL 
tumor suppressor gene, with Type 2B missense VHL mutations predisposing to 
renal cell carcinoma, hemangioblastoma, and pheochromocytoma. Type 2B 
mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-α 
regulation.  Interaction analysis in VHL –transgenic murine embryonic stem (ES) 
and renal cell carcionoma-derived cell lines supported previous observations that 
VHL Type 2B mutations disrupt the interaction between pVHL and Elongin C but 
maintain partial regulation of HIF-α, most likely via a remnant complex containing 
ROC1 and Cullin-2 and reduced or absent Elongin C.  Murine embryonic stem 
(ES) cells in which the endogenous wild-type Vhl gene was replaced with the 
representative Type 2B VHL hotspot mutation R167Q (Vhl2B/2B) likewise 
displayed preserved physiologic regulation of both HIF factors with slightly more 
normoxic dysregulation of HIF-2α.  Differentiated Vhl2B/2B-derived teratomas over-
expressed the joint HIF targets Vegf and EglN3 but not the HIF-1α-specific target 
Pfk1 and displayed a growth advantage over Vhl-/--derived teratomas, suggestive 
of a tight connection between perturbations in the degree and ratio of HIF-1α and
iv 
 
HIF-2α stabilization and cell growth.  Vhl2B/2B mice displayed mid-gestational 
embryonic lethality, while adult Vhl2B/+ mice exhibited susceptibility to carcinogen-
promoted renal neoplasia compared with wild-type littermates at twelve months.  
Our experiments support a model in which the representative Type 2B R167Q 
mutant pVhl retains intermediate HIF-α suppression via formation of a remnant 
ubiquitin ligase complex, thereby producing a unique profile of HIF-α 
dysregulation with tissue-specific effects on cell growth, development, and tumor 
predisposition. 
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CHAPTER ONE 
Introduction 
 
Framing the clinical problem: renal cell carcinoma 
 An estimated 54,390 new cases of renal cell carcinoma (RCC) were 
diagnosed in the United States in 2008(1).  Alarmingly, the incidence of RCC in 
the United States has been rising by approximately two percent per year since 
1975(2).  While the five-year survival for individuals with localized disease at 
diagnosis approaches 90%, 20-30% of patients present with distant metastases 
and face a five-year survival of <10%.  In 2008, and estimated 13,010 people 
died from RCC in the United States.  RCC is two times more common in men 
than in women.  Other known risk factors for RCC include smoking, overweight 
and obesity, hypertension, kidney transplant and dialysis, and occupational 
exposure to organic solvents such as trichloroethylene(1, 3, 4).   
 RCC is a heterogeneous disease.  According to the Heidelberg 
classification system, RCC can be divided into the following histological 
subtypes: clear cell (cc) RCC (75%), papillary Type I and Type II (15%), 
chromophobe (4%), and oncocytoma (benign, 4%) (5, 6)(Figure 1.1).  Clear cell 
RCC tumors are highly vascular and glycolytic and contain cells with abundant
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clear lipid and glycogen-containing cytoplasm.  The vast majority of sporadic 
ccRCC at all tumor stages feature mutation or silencing of the von Hippel-Lindau 
(VHL) tumor suppressor gene, loss of the short arm of chromosome 3, or LOH 
(LOH) at the VHL locus, implicating loss of wild-type VHL as an early or initiating 
event in ccRCC(8).  Broadly, the architecture of papillary RCC consists of finger-
like projections called papillae.  The papillae of Type 1 papillary RCC tumors are 
composed of small, pale cells with small nuclei, while the papillae of Type 2 
papillary RCC tumors are composed of large eosinophilc cells with large nuclei, 
distinct nucleoli, and a pseudostratified appearance.  Sporadic Type 1 papillary 
RCC is strongly associated trisomy 7 and 17 and loss of the Y chromosome in 
men (9)and more rarely with activating mutations in the MET proto-oncogene 
(7q31-34)(10-12).  Chromophobe RCC features sheets of cells with abundant 
clear, reticulated cytoplasm, irregular nuclei with perinuclear halo, and prominent 
cell membranes.  Sporadic chromophobe RCC tumors tend to have multiple 
chromosomal losses, typically of chromosomes 1, 2, 6, 10, and 17(13-15).  Other 
types of adult kidney cancer, histologically and/or` mechanistically distinct from 
renal cell carcinoma, include collecting duct carcinoma, TFE3 translocation 
carcinoma, medullary carcinoma, and urothelial carcinoma.  The most common 
pediatric kidney cancer is Wilm’s tumor.  This dissertation will focus on ccRCC, 
the histological subtype responsible for the greatest burden of kidney cancer 
morbidity and mortality in the adult population.     
 Surgical treatment is the standard-of-care for both local and metastatic 
RCC (16).  RCC is highly resistant to standard chemotherapeutic agents, and 
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only a handful of drugs have been approved by the Food and Drug 
Administration (FDA) for the treatment of advanced RCC: the immunomodulatory 
drug interleukin (IL)-2 (high-dose), the mammalian target of rapamycin (mTOR) 
inhibitors temsirolimus and everolimus, and the small molecule receptor tyrosine 
kinase (RTK) inhibitors sorafenib and sunitinib.  Sorafenib and sunitinib target 
multiple RTKs, including vascular endothelial growth factor (VEGF)-receptor and 
platelet-derived growth factor (PDGF)-receptor families, thought to be expressed 
on the tumor-supporting cells rather than the tumor cells themselves.  Both 
mTOR inhibitors(17, 18) and RTK inhibitors (19, 20) roughly double progression-
free survival (PFS) in highly selected populations but tend to stabilize disease 
rather than induce remissions and thereby fail to impact overall survival.  The 
relative paucity of effective adjuvant therapies for RCC reflects a need for greater 
understanding of the molecular mechanisms underlying the initiation and 
progression of renal tumorigenesis. 
The VHL tumor suppressor gene and VHL Disease 
 The VHL tumor suppressor gene (3p25) was isolated in 1993 by positional 
cloning (21).  VHL contains three exons and encodes a 24-30 kDa protein 
pVHL30.  An internal transcriptional start site in the VHL gene also yields pVHL19, 
a shorter 19 kDa isoform with overlapping or identical function (22, 23).  
Hereafter, “pVHL” will be used when both isoforms are indicated.  The VHL 
protein is ubiquitously expressed in human fetal and adult tissues (24-26).  
 Germline mutations in VHL result in VHL Disease.  VHL Disease has an 
incidence of approximately 1:36,000 live births and is 90% penetrant by age 65 
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(27, 28).  Approximately 20% of VHL Disease kindreds arise from new mutations 
(29).  VHL Disease predisposes to benign and malignant tumors in several, but 
not all, pVHL-expressing tissues: hemangioblastomas of the retina, brainstem, 
cerebellum, and spinal cord; tumors of the endolymphatic sac; adrenal gland 
pheochromocytomas and extra-adrenal paraganglinomas; renal cysts and 
ccRCC; pancreatic cysts, neuroendocrine tumors and cystadenomas; and 
cystadenomas of the epididymis (in males) and broad ligament (in females).  
Retinal and CNS hemangioblastomas, pheochromocytomas, and RCC are 
responsible for the majority of VHL Disease-associated morbidity and mortality 
(reviewed in (30)).   
 Hemangioblastomas are the most common VHL Disease-associated 
lesion, occurring in 60-80% of VHL Disease patients (31, 32).  The mean age at 
diagnosis is 25 years for retinal (33) and 33 years for craniospinal lesions (32).  
Hemangioblastomas most commonly develop in the cerebellum and the spinal 
cord (34).  Hemangioblastomas consist of a VHL-deficient neoplastic stromal 
mass associated with an abnormal, dense vascular network (35).  Though 
histologically benign, CNS hemangioblastomas and associated peritumoral 
edema and cysts cause substantial neurological morbidity by mass effect.  
Cerebellar hemangioblastomas, for example, may cause gait ataxia, dysmetria, 
headache, diplopia, and nausea and vomiting, while spinal hemangioblastomas 
may be associated with segmental hypaesthesia, weakness, and pain, hyper-
reflexia, gait ataxia, and incontinence (32).  Retinal hemangioblastomas may 
cause visual disability or blindness.  Hemangioblastomas also carry the risk of 
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bleeding or hemorrhage.  Treatment of hemangioblastomas typically consists of 
surgical excision of the solid component with collapse of any associated cysts 
and resolution of edema following naturally (36).  Clinical trials are underway, 
however, studying the use of targeted anti-angiogenesis therapy in the 
neoadjuvant or preventative setting in VHL Disease patients.  Longitudinal 
radiographic studies of natural history suggest that most VHL Disease-
associated hemangioblastomas grow in a salutatory manner, with quiescent 
periods interspersed between intervals of rapid growth (32, 34).  Given that VHL 
Disease patients often develop multiple asynchronous lesions over the course of 
a lifetime, the decision to treat surgically must balance radiographic evidence of 
progression and clinical evidence of morbidity against the morbidity associated 
with multiple surgical procedures.  
 Pheochromocytomas occur in 10-20% of all VHL Disease patients, with 
greater penetrance in selected groups (described below), and are malignant in 
5% of cases.  The median age of onset for pheochromocytoma is 30 years of 
age (range 5-58 years) (37).  Pheochromocytomas arise from chromaffin cells in 
the adrenal medulla and may secrete epinephrine and/or norepinephrine in a 
continuous or episodic fashion.  Though 1/3rd of VHL Disease patients with 
pheochromocytoma are asymptomatic, the remaining 2/3rd show signs and 
symptoms of catecholamine secretion such as palpitations, diaphoresis, and 
hypertension (37).  VHL Disease patients may also present with extra-adrenal 
pheochromocytomas or paragangliomas, for example in the jugular glomus,  
carotid body, or periaortic ganglia.  Pheochromocytomas are usually treated by 
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adrenalectomy or enucleation with the goal of preserving adrenal cortical function 
(38, 39).  In the case of disseminated or metastatic pheochromocytoma when 
surgical excision is not possible, α-adrenergic blocking drugs are used to prevent 
hypertensive crisis associated with secretion of norepinephrine and/or 
epinephrine.  VHL loss is not commonly observed in sporadic 
pheochromocytomas (40).   
 Finally, renal cysts and/or ccRCC occur in 60% of VHL Disease 
individuals (41, 42) and contribute to the bulk of VHL Disease-associated 
mortality.  Renal cysts are thought to be the precursor lesion for most or all 
ccRCC tumors associated with VHL Disease.  Histological examination of grossly 
normal VHL Disease kidney tissue reveals hundreds of renal cysts and small 
tumors (43) as well as VHL inactivation in morphologically single cells (44).  
Statistically, the chance of a single cyst or small tumor out of hundreds 
progressing to a malignancy is substantial (45).  RCC associated with VHL 
Disease displays clear cell histology and tends to be small and low-grade at the 
time of diagnosis (43).  Surgical management of VHL Disease-associated RCC 
tends towards nephron-sparing partial nephrectomy in an effort to preserve renal 
function (46). 
 Endolymphatic sac tumors are less common (10% of VHL Disease 
patients) than hemangioblastoms, pheochromocytomas, and ccRCC, but are 
associated with substantial morbidity (47).  Endolymphatic sac tumors uniformly 
present with partial or complete hearing loss and may additionally be associated 
with tinnitus and vertigo.  Resection of endolymphatic sac tumors is curative and 
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usually maintains pre-operative hearing capacity but carries a risk of auditory or 
facial nerve damage. 
 VHL Disease patients adhere to a strict schedule of radiographic and 
clinical examinations and laboratory tests in order to identify new and monitor 
progression of established lesions and to minimize morbidity and mortality (30).  
Retinal hemangioblastomas and pheochromocytomas have been discovered in 
children with VHL Disease, so retinal exams are encouraged yearly beginning in 
infancy and yearly plasma or 24-hour urine catecholamine and metanephrine 
levels are suggested beginning at age two or with onset of hypertension.  
Screening for CNS hemangioblastomas begins at age eleven with magnetic 
resonance imaging (MRI) scan of the craniospinal axis.  Finally, radiographic 
screening for visceral lesions such as pheochromocytoma, renal cysts and RCC, 
and pancreatic cysts and tumors, begins at age eight with yearly abdominal 
ultrasounds and at age eighteen with yearly abdominal computed tomography 
(CT) scans.  MRI and CT scans of the auditory canal and audiometric testing are 
reserved until signs or symptoms of an endolymphatic sac tumor, such as 
vertigo, tinnitus, or hearing loss, arise.  Lesions displaying radiographic evidence 
of progression and/or associated with clinical signs or symptoms of morbidity 
prompt more frequent examination. 
 VHL mutations fall into distinct classes with unique spectrums of clinical 
disease (48, 49).  Type 1 patients (deletion/truncation mutations) have high 
ccRCC and low pheochromocytoma incidence (50).  Type 2 patients (missense 
mutations) all have high risk of pheochromocytoma, either alone (2C) or in 
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addition to hemangioblastoma and low (2A) or high (2B) risk of ccRCC (51).  
Homozygosity for the VHL R200W mutation results in Chuvash Polycythemia, 
associated with polycythemia and elevated risk for thrombotic events but no 
increased cancer risk(52-54).   This dissertation focuses on the VHL 2B subtype. 
VHL protein structure and function 
 Structure of pVHL and VBC complex.  The VHL protein acts as the 
recognition component of a complex with ubiquitin ligase activity.  pVHL consists 
of an α domain and a β domain.  The pVHL α domain consists of three α helices 
(H1-3, residues 155-192) which coordinate with a fourth α helix from Elongin C to 
generate an intermolecular four-helix bundle (55).  The H1 α helix overlaps with 
the Elongin C binding domain (residues 157-171) determined empirically in 
earlier biochemical studies (56, 57).  The pVHL α domain interacts directly with 
Elongin C, which in turn recruits the co-adaptor Elongin B, the scaffolding protein 
cullin-2 (CUL2) (58, 59), and the RING domain protein RBX1/ROC1(60).   The 
pVHL β domain consists of a seven-strand β sandwich (residues 63-154) and an 
N-terminal α helix (H4, residues 193-204) (55).  The complex of pVHL with 
Elongins B and C is referred to as the VBC complex.   
 The VBC complex with CUL2 shares similarities with the yeast 
Skp1/Cul1/F-box (SCF) complex: Elongin C and CUL2 share sequence identity 
with Skp1 and Cul1, respectively, and the pVHL α domain shows a similar 
hydrophobicity profile and structural similarity with F-box protein (55).  Analogous 
to F-box function in yeast SCF, the pVHL β domain targets specific proteins to 
VBC ubiquitin ligase activity (61, 62).  Known and putative targets of pVHL 
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ubiquitin ligase activity include the hypoxia-inducible factors (HIF)-1α and -2α 
(63-66), atypical protein kinase C (aPKC) isotypes (67), VHL-interacting 
deubiquitinating enzymes (VDU)-1 and -2 (68), and two subunits of RNA 
polymerase II Rpb7(69) and Rpb1(70). 
  HIF-1α and HIF-2α are the most well-described substrates for pVHL 
ubiquitin ligase activity.  HIF-1α and HIF-2α are basic helix-loop-helix (bHLH) – 
Per Arnt Sims (PAS) transcription factors.  Briefly, under normal oxygen 
conditions, specific prolyl residues in the oxygen-dependent degradation domain 
(ODDD) of hypoxia-inducible factor (HIF)-1α and -2α are hydroxylated.  The 
pVHL β domain binds and targets prolyl hydroxylated HIF-α for ubiquitination and 
degradation by the 26S proteasome.  Under hypoxic conditions, the ODDD is not 
hydroxylated, precluding targeting by pVHL (71-75).  Stabilized HIF-α then 
accumulates, translocates to the nucleus, and heterodimerizes with aryl 
hydrocarbon receptor nuclear transferase (ARNT)/HIF-1β (76), and binds and 
activates transcription at consensus hypoxia-responsive elements (HRE, CGTG) 
(77, 78).  HIF-1α and HIF-2α target gene repertoires are overlapping but distinct 
(79).  Joint HIF-1α/HIF-2α targets include VEGF, GLUT-1, EGLN3, and ADM (80-
83).  The highly evolutionarily conserved HIF-1α uniquely activates such genes 
as those encoding the glycolytic pathway(83), pyruvate dehydrogenase kinase 
(PDK) 1 (84), and BNIP-3 (85).  Finally, HIF-2α regulates a diverse set of genes, 
including OCT-4 (86), cyclin D1 (87), TWIST (88), TGFα (89), and EPO (90). 
 Non-ubiquitin ligase activities.  Known non-ubiquitin ligase activities of 
pVHL include promotion of cellular senescence (91), assembly and maintenance 
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of cytoskeletal components (92, 93) and proper deposition of extracellular matrix 
proteins (94, 95).  Acute inactivation of Vhl in mouse embryonic fibroblasts (MEF) 
results in persistant growth arrest and features of senescence, including flattened 
morphology, expression of senescence-associated β galactosidase (SABG), and 
formation of heterochromatic foci.  Surprisingly, senescence in Vhl-deficient 
MEFs is independent of HIF and p53 and but dependent on activated 
(hypophosphorylated) Rb.  Vhl loss in MEFs results in post-transcriptional 
reduction in the chromatin remodeling factor p400, directly or indirectly promoting 
post-transcriptional reduction in Skp2, the ubiquitin ligase for the cyclin-
dependent kinase inhibitor p27Kip1.  Stabilized p27Kip1 then activates Rb.  
Activated Rb is both necessary and sufficient for senescence in Vhl-deficient 
MEFs.  Acute somatic inactivation of Vhl in the mouse is also associated with 
SABG-positivity and p27 stabilization in the kidney, providing a possible 
mechanistic explanation for the refractoriness of the murine kidney to renal 
tumorigenesis.  Relevance of this function of VHL in human disease is uncertain, 
as VHL loss in human cell lines reduces proliferation but does not cause 
senescence or stabilize p27 (91), and p400-mediated senescence in human cells 
is p53-dependent and Rb-independent (96). 
   The VHL protein regulates the deposition of extra-cellular matrix via 
direct interactions with fibronectin(95), an integrin-binding protein, and collegen 
IV(97, 98).  The direct interaction of pVHL with fibronectin requires conjugation of 
NEDD8 to K159 (95), a modification that simultaneously hinders pVHL 
association with CUL2 (99).  pVHL-FN associates with the membrane fraction, 
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most likely with the endoplasmic reticulum (ER) and Golgi.  The VHL-fibronectin 
interaction is required for the secretion and deposition of fibronectin in 
extracellular fibrillar arrays (95).  The VHL protein also directly interacts with a 
component of collegen IV, specifically hydroxylated collagen IVa2(97, 98).  
Hydroxylated collagen IVa2 binds the pVHL β domain via one of its HIF-α 
hydroxylprolyl binding pockets in a presumably mutually exclusive interaction 
(98).  VHL protein is required for deposition of a collagen IV matrix in the 
basement membrane both in vitro in cell culture and in xenografts.  All Type 1, 
2A, 2B, and 2C VHL mutants tested thus far are defective for fibronectin 
deposition (51, 95, 100), while the Type 2C but not 1, 2A, or 2B VHL mutants 
tested retain a small degree of collagen IVa2 capture (97). 
 Finally, pVHL binds cytoplasmic microtubules and, in a tightly related 
function, contributes to the maintenance of the primary cilium.  VHL30 but not 
VHL19 binds directly to microtubules, partitioning to the cytoplasm at the 
microtubule organizing center (MTOC) and at the cell periphery.  VHL protects 
microtubules from depolymerization by nocodozole(93) and additionally appears 
to control or assist in proper microtubule orientation.  In VHL wild-type cells, 
microtubules orient towards the cell periphery, while microtubule orientation is 
haphazard in VHL-deficient cells(101).   
 The primary cilium is a single organelle extending from the apical cell 
membrane (reviewed in (102, 103)).  The structure of the primary cilium consists 
of microtubules in a 9 + 0 arrangement arising from the centriole, variously 
known as the basal body or as the MTOC during mitosis.  The general function of 
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the primary cilium is to interpret sensory information such as air or fluid flow and 
to transduce extracellular signals.  The VHL protein is dispensible for the initial 
formation of the primary cilium but contributes, along with GSK3β, to its 
maintenance(104).  In conditions under which GSK3β is active, GSK3β 
phosphorylates pVHL on a specific serine residue, rendering pVHL capable of 
binding but not stabilizing microtubules(105), and independently maintains the 
integrity of the primary cilium (104).  When GSK3β is inactive or deficient, for 
example due to growth factor signaling, primary cilium maintenance falls to 
pVHL.  VHL mutants that fail to bind cytoplasmic microtubules are likewise 
deficient in primary cilium maintenance (104).  The role of the primary cilium in 
renal cyst formation will be discussed in more detail below.  
In Vitro Models of VHL Disease 
 The distinct genotype-phenotype correlations of VHL disease suggest that 
disruption of wild-type or introduction of novel pVHL functions contribute to VHL 
Disease tissue specificity.  In vitro transgenic models of VHL Disease in both 
RCC-derived and murine embryonic stem (ES) cell lines show disconnection 
between Elongin C and HIF-α binding and RCC predisposition.  VHL-null RCC 
and ES cells cannot target HIF-α for degradation, resulting in abnormal normoxic 
accumulation of HIF-α and its target gene products.  Complementation with wild-
type VHL restores HIF-α regulation in these models.  Complementation of RCC 
cells with 2A and 2B VHL mutants results in impaired HIF-α binding, while 2B 
VHL mutants additionally fail to recruit Elongin C (51, 106).  In xenograft assays 
using RCC cells, VHL-null cells enhance tumor growth, while wild-type VHL and 
14 
 
all mutants except 2A suppress tumor growth.  In ES cell teratoma assays, 
however, Vhl-null cells display suppressed growth compared to wild-type VHL-
expressing cells.  While type 2B VHL expression restores wild-type growth, 2A 
mutants retain the growth-suppressive phenotype (106, 107).  Combined with 
recent evidence that HIF-2α can act as a tumor suppressor (108), the teratoma 
data weakens the assumption of a direct relationship between HIF dysregulation 
and RCC predisposition.  Pheochromocytoma predisposition also appears to be 
HIF-independent, instead related to impaired c-Jun-dependent developmental 
culling of sympathetic neuronal precursors in response to nerve growth factor 
(NGF) withdrawal (109).   
In Vivo Models of VHL Disease 
 Genetically engineered mouse models of human cancer are useful for 
understanding cancer biology and preclinical development and testing of 
therapeutic drugs.  The majority of models of human VHL Disease currently in 
existence utilize null and conditional Vhl alleles, often in combination with tissue-
specific promoter-driven and inducible cre recombinase activity.  Though such 
conditional models of Vhl loss circumvent the mid-gestational lethality associated 
with germline nullizygosity for Vhl (110, 111), they assume a specific cell type of 
origin and/or temporal window of susceptibility to tumor initiation.  Use of a null or 
conditional null allele of Vhl also fails to capture and take advantage of the strict 
genotype-phenotype correlations observed in VHL Disease and ideal for 
separating and defining Vhl functions.  To that end, an endogenous gene 
replacement model of Chuvash Polycythemia has been generated recently which 
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recapitulates the human disease(112).  The developmental and tumor 
predisposition phenotypes of germline and mosaic knock-out models of Vhl and 
pertinent HIF axis members will be discussed first, followed by tissue-specific Vhl 
models with or without HIF rescue (summarized in Table 1.1).  
 Germline and mosaic loss of murine Vhl.  Three independent mouse 
lines utilizing null or conditional null alleles of Vhl have been developed and 
characterized.  In 1997, Gnarra et al. published the first mouse model of VHL 
Disease(110).  Mice heterozygous for a null Vhl allele (Vhl+/-) were generated in a 
mixed C57BL/6 genetic background.  Vhl+/- mice were aged to 15 months and did 
not display evidence of neoplasia.  Inter-heterozygous matings revealed a 2:1 
ratio of Vhl+/- to Vhl+/+ mice and an absence of live-born Vhl-/- progeny, and timed 
mating analysis pinpointed the window of embryonic demise to embryonic day 
(E) 10.5-12.5.  Because mouse embryos transfer dependency from the yolk sac 
to the placenta around E9.5-10.5 and Vhl-/- embryos were grossly and 
morphologically normal until E10.5, the time point of Vhl-/- embryonic demise was 
suggestive of placental failure.     
 The murine placenta consists of three layers: the labyrinth, 
spongiotrophoblast, and maternal decidua (reviewed in (113, 114)).  The 
labrythine layer consists of highly branched embryonic-origin allantoic vessels 
surrounded by sheets of chorionic trophectoderm-origin syncitiotrophoblasts and 
bathed in maternal blood.  The labyrinthine layer provides a vital transport 
function, providing oxygen and nutrients across the thin syncitiotrophoblast layer
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to and fetal waste away from the fetal circulation.  The labyrinth is supported by 
spongiotrophoblast cells, derived from the trophectoderm of the ectoplacental 
cone, and is separated from the maternal decidual uterine tissue by a layer of 
polyploid trophoblast giant cells.  The murine placenta derives from the 
trophectoderm layer of the inner cell mass and the extra-embryonic mesoderm 
(allantois).  At E8.5, the embryonic allantois fuses with the chorionic plate in a 
process called chorioallantoic attachment.   After attachment, from E8.5-10.5, the 
chorionic plate folds into villi as the allantoic vessels migrate into the inter-villous 
spaces.  In a mutual induction process, the allantoic vessels and chorionic plate 
villi undergo branching morphogenesis to form the maze-like labyrinth, and the 
chorionic trophoblasts adjacent to fetal blood vessels differentiate into 
syncitiotrophoblasts.  The murine placental labyrinth is analogous in structure 
and function to human chorionic villi. 
 Vhl-/- placentas developed normally until E9.5, exhibiting proper 
chorioallantoic fusion and morphologically normal chorionic trophoblasts.  At 
E10.5, however, no allantoic vessels had penetrated the chorionic plate, 
maintaining complete separation of maternal and fetal circulation.  Between 11.5-
12.5, Vhl-/- placental labyrinths became hemorrhagic and embryos became 
necrotic.  Immunohistochemical studies demonstrated that wild-type placentas 
expressed pVhl in both extra-embryonic (labyrinthine trophoblasts and allantoic 
mesoderm) and embryonic (endothelial) tissues. 
 Several years later, the Gnarra Vhl+/- mouse line was used by another 
research group in mutagenesis studies(115).  Vhl+/- and control Vhl+/+ mice 
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received intraperitoneal (i.p.) injection of the renal mutagen streptozotocin (50, 
100, 150, or 200 mg/kg) at 8 weeks of age.  Streptozotocin induced renal cyst 
formation equally well in Vhl+/- and Vhl+/+ mutagenized mice at 14-15 months.  
Interestingly, approximately 20% of untreated Vhl+/- mice aged 14-17 months 
developed hepatic angiomas, vascular liver tumors uncommon in human VHL 
Disease and not observed in the original study of this mouse line.  Streptozotocin 
significantly enhanced hepatic angioma formation in Vhl+/- mice relative to 
untreated Vhl+/- mice and mutagenized Vhl+/+ controls, increasing penetrance 
from ~20% to 33% at 150 mg/kg and 46% at 200 mg/kg at 14-15 months.    
 In 2001, Haase et al. published a second mouse model of VHL Disease 
utilizing a Vhl allele flanked by loxP sites (floxed, f) and the corresponding 
recombined Vhl-deleted (d) allele in a mixed Balb/c background(111).  Vhld/d 
embryos died at E9-11 with a placental phenotype identical to that observed in 
the Gnarra et al. Vhl-/- model.  In a significant departure from the original Gnarra 
et al. Vhl+/- model, Vhld/+ mice developed hepatic angiomas in an age-dependent 
fashion.  Approximately 50% of Vhld/+ mice aged to 3-11 months and more than 
90% of Vhld/+ mice aged 12-17 months developed large hepatic vascular cavities 
associated with steatosis and small vessel proliferation.  Only 1/30 Vhld/+ mice 
developed a renal microcyst (3%), the presumptive precursor lesion to RCC, and 
none developed pheochromocytoma. 
 Ma et al. independently derived a third VHL Disease mouse model utilizing 
floxed or deleted Vhl on a C57BL/6 background alone or in combination with 
mosaic promoter-driven cre recombinase (116) and with tamoxifen-inducible cre 
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recombinase (117).  In an effort to circumvent embryonic lethality and mimic 
stochastic loss of heterozygosity (LOH) in VHL Disease patients, Ma et al. first 
characterized the floxed Vhl allele using a human β-actin- cre transgenic mouse 
line(116).  The particular β-actin-cre mouse line used was chosen for its 
stochastic expression in early embryonic development, resulting in mosaic Vhl 
LOH in adult tissues, and minimal expression in placental tissues.  β-actin-
cre;Vhlf/d mice were viable and developed hepatic angiomas with complete 
penetrance at time points ranging from 4-12 months.  β-actin-cre;Vhlf/d mice also 
developed renal, pancreatic, and hepatic angiectasis (enlarged blood vessels) 
and male infertility due to defective spermatogenesis.  In light of the large 
variation in hepatic angioma penetrance between the Gnarra et al. Vhl+/- 
(C57BL/6, 0-20% at 15 months) mouse line and the Haase et al. Vhld/+ (Balb/c, 
>90% at 12-17 months), Ma et al. also back-crossed the Vhl-deleted allele to two 
additional genetic backgrounds.  Vhlf/d mice on the original mixed C57BL/6 
background displayed 18% penetrance of hepatic angiomas at 12 months, while 
hepatic angiomas were 88% penetrant in Vhld/+ mice on Balb/c and 67% 
penetrant in Vhld/+ mice on A/J at 18 months.      
 Hong et al. used a tamoxifen-inducible cre recombinase-oestrogen 
receptor fusion receptor fusion transgene (CreERTM) system as a second 
approach to circumvent embryonic lethality in the Ma Vhl model (117).  CreER is 
sequestered and inactive in the absence of estrogens.  Ingestion of tamoxifen 
(TAM) by mature animals with subsequent binding of TAM to CreER results in 
nuclear translocation and functional activation of cre recombinase to mediate 
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recombination between loxP sites in affected cells.  CreERTM;Vhld/+ mice were 
crossed to Vhlf/f mice, and pregnant dams were injected with 2-4 mg TAM at 
E10.5.  Acute Vhl loss at E10.5 delayed embryonic lethality until E13.5-15.5.  
CreERTM;Vhld/f + TAM embryos during this window displayed gross dorsolateral 
hemorrhage and body necrosis, associated with dilated, leaky vessels and focal 
liver necrosis on histological examination.  The CreERTM;Vhld/f + TAM placentas 
were morphologically normal at E14.5 but displayed a mild decrease in 
labyrinthine layer thickness with dilated blood vessels and mislocalized 
spongiotrophoblast cells at E16.5, suggestive of a greatly reduced or delayed 
placental phenotype.   
 Altogether, Vhl null and mosaic null mouse models exhibit a requirement 
for murine placental and embryonic development in mid-gestation and a 
predisposition to hepatic angioma but not renal cysts or RCC.   
 Germline loss of hypoxia-inducible factor and related genes.  In 1998, 
Iyer et al. published a mouse model utilizing a null allele for Hif1a (118).  
Nullizygosity for Hif1a conferred embryonic lethality at E10-11 on both C57BL/6 
and 129 genetic backgrounds.  Hif1a-/- lethality was preceded by developmental 
arrest (reduced somite number) at E8 and morphological changes at E9.  E9 
Hif1a-/- embryos displayed neural tube defects associated with replacement of 
cephalic mesenchyme by dilated vessels; abnormal vasculature including the 
branchial arch, dorsal aorta, and intersomitic vessels; and myocardial 
hyperplasia with pericardial effusion. 
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 Three independent models of Hif2a loss were developed with drastically 
different phenotypes (81, 119, 120).  The Hif2a knock-out model developed by 
Tian et al. exhibited embryonic lethality at E12.5-16.5 (120).  Hif2a-/- embryos did 
not display vascular defects and possessed a histologically normal placenta, 
suggestive of a physiological cause of lethality.  Hif2a-/- mice were determined to 
have bradycardia and low norepinephrine levels, postulated to result from a 
requirement for Hif2a in catecholamine biosynthesis in adrenal chromaffin cells.  
Embryonic lethality was partially rescued by treating pregnant dams with D,L-
threo-3,4-dihydroxyphenylserine (DOPS), which could be directly converted to 
norepinephrine by decarboxylase activity in utero.  Surviving Hif2a-/- mice died 
within 24 hours.      
 Hif2a-/- mice developed by Peng et al. displayed vascular defects with 
variable penetrance(119).  One third of Hif2a-/- mice on an outbred 129Sv/ICR 
background were viable for several weeks, while the remaining two thirds 
displayed embryonic lethality at E9.5-13.5.  Death in utero was associated with 
subtle defects in vascular remodeling especially apparent in the yolk sac and 
only rarely observed in the embryo and variably associated with embryonic 
hemorrhage.  Hif2a-/- embryonic lethality was partially rescued by DOPS 
treatment, with rescued animals surviving for less than 24 hours, suggesting that 
reduced catecholamine biosynthesis featured in embryonic demise.  Hif2a-/- mice 
on a congenic 129Sv background uniformly displayed embryonic lethality at 
E9.5-12.5, associated with defective vascular remodeling in both the yolk sac 
and the embryo proper. 
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 In a third model by Compernolle et al., 50% of Hif2a-/- mice on a mixed 
129Sv/Swiss genetic background died at E13.5 due to cardiac failure, while the 
remaining 50% died two-three hours post-natally (81).  Post-natal death was due 
to respiratory distress syndrome (RDS) due to a maturation defect in the 
surfactant-producing Type II pneumocytes.  The lungs of surviving Hif2a-/- 
neonates also subtle vascular defects.  Neither embryonic nor post-natal lethality 
was rescued by DOPS treatment in utero. 
 Two independent models of Arnt loss have also been developed and 
characterized (121-124).  Arnt is the heterodimerization partner for HIF-α 
subunits and is required for HIF-α transcriptional activity.  Arnt-/- mice on a mixed 
129SvJ/C57BL/6 background display embryonic lethality at E9.5-10.5 (124).  At 
E9.5-10.5, Arnt-/- yolk sacs were essentially avascular but embryonic 
vasculaturization was normal except for a mild defect in capillary formation in 
solid organs(124).  Preceding embryonic lethality at E8.5, the Arnt-/- placenta 
contained all the proper cell lineages, including 4311-positive spongiotrophoblast 
cells and placental lactogen (PL)-1-positive trophoblast giant cells and an 
unidentified population of double-positive cells, but were slightly smaller than 
wild-type and Arnt+/- placentas.  The E9.5 Arnt-/- placenta displayed an absence 
of fetal vessels in the labyrinth and evidence of shallow invasion of the maternal 
myometrium.  Histologically, E9.5 Arnt-/- placentas contained very few 4311-
positive spongiotrophoblasts and an expanded population of PL-1-positive 
trophoblast giant cells (121).  
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  In order to determine whether the observed placental defect was 
embryonic or trophoblastic in origin, diploid Arnt-/- ES cells were aggregated with 
tetraploid wild-type morulas in a technique referred to as tetraploid 
aggregation(121).  Tetraploid cell contribution is limited to the extra-embryonic 
lineages, resulting in an Arnt-/- embryo with a wild-type placenta (excluding the 
contribution of Arnt-/- embryonic-origin allantoic vessels to the labyrinth).  
Tetraploid aggregation slightly delayed embryonic lethality until E10.6 and 
rescued the placental defects, demonstrating that the defects in labyrinthine 
vascularization and altered trophoblast differentiation resulted from Arnt 
deficiency in the trophoblast lineage.  Rescued embryos at E10.6 displayed 
severe cardiac hypoplasia, possibly the causative lesion for the absence of yolk 
sac vascularization(121). 
 In order to determine the relative contributions of Hif1a and Hif2a loss of 
function in Arnt models, Cowden et al. compared Arnt-/- development to Hif1a and 
Hif2a placental development singly and in combination(122).  In their hands, 30% 
of E9.5 Hif1a-/- placentas failed chorio-allantoic attachment, while the remaining 
70% fused properly but allantoic vessels failed to migrate into the chorionic plate.  
E9.5 Hif1a-/- labyrinths showed a 50% reduction in Tpbp-positive 
spongiotrophoblast cells but a normal number of PL-1-positive trophoblast giant 
cells.  Hif2a-/- placentas at E9.5 displayed normal chorioallantoic fusions, allantoic 
vascularization of the chorionic plate, and spongiotrophoblast and giant cell 
populations.  Double Hif1a-/-;Hif2a-/- mutant placentas at E9.5 were identical to 
Arnt-/- placentas at E9.5, displaying complete failure of chorioallantoic 
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attachment, no vascular invasion of the chorion, an absence of 
spongiotrophoblast cells, and an expanded population of trophoblast giant cells.  
Indicating that HIF dosage is critical in placental development, Hif1a-/- in 
conjunction with heterozygosity for Hif2a loss resulted in a placental phenotype 
nearly as severe as the Arnt-/- phenotype. 
 Kozak et al. published a second independent mouse model of Arnt 
deficiency using a similar targeting strategy (replacement of the sequence 
encoding the Arnt bHLH domain) and a nominally similar genetic background 
(mixed 129SvJ/C57BL/6) to the mice derived by Maltepe et al. but with a more 
severe embryonic and less severe placental phenotypic outcome.  Nullizygosity 
for Arnt conferred embryonic lethality at E9.5-10.5 (123).  E9.5 Arnt-/- embryos 
were slightly growth-retarded.  E10.5 Arnt-/- embryos were clearly 
developmentally delayed as evidenced by reduced somite number and were 
afflicted with neural tube defects and forebrain hypoplasia.  E10.5 Arnt-/- embryos 
were associated with normal yolk sacs.  The corresponding E10.5 Arnt-/- 
placentas were hemorrhagic and displayed reduced labyrinthine vascularization 
but uniformly succeeded in chorioallantoic fusion. 
 The preceding mouse models of Hif1a, Hif2a, and Arnt deficiency 
demonstrate a broad requirement for HIF-α activity in the murine placental 
trophoblast lineage as well as in development of the embryonic cardiovascular, 
nervous, and respiratory systems.  The lack of embryonic models of constitutively 
stabilized Hif1a and Hif2a prevents direct analysis of the impact of over- or mis-
expression of HIF-α on murine development.  Takeda et al., however, developed 
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mouse models of proly hydroxlase domain (Phd) 1, 2, and 3 deficiency (125).  
Phd proteins hydroxylate specific prolyl residues on the HIF-α ODD (71, 72, 74, 
126-130), thereby targeting HIF-α to the pVhl β domain for ubiquitylation and 
proteasome mediated degradation (73, 75).  Given that the embryo and placenta 
are hypoxic environments during development and that Phd activity is limited to 
normal oxygen conditions in vitro (127, 131), the impact of Phd deficiency, if any, 
on HIF stability and/or development was difficult to predict.   
 Indeed, Phd1-/- and Phd3-/- mice were viable and displayed no embryonic 
or placental defects.  Phd2-/- mice died in utero between E12.5-14.5 due to 
cardiac failure(125).  Phd2-/- yolk sacs and embryos displayed no gross defects in 
vessel patterning, but Phd2-/- embryos did display defective ventricular 
maturation by E11.5.  Phd2-/- placentas appeared normal at E9.5 but showed 
reduced chorionic villus folding and with an equivalent reduction in fetal blood 
vessel content in the presumptive labyrinth at E12.5, suggestive of defective 
trophoblastic branching morphogenesis.  E12.5 Phd2-/- placentas also contained 
an abnormal distribution of trophoblast giant cells and spongiotrophoblast cells.  
Phd2-/- embryos and placentas both demonstrated HIF-1α and HIF-2α 
stabilization relative to wild-type and Phd2+/-, confirming that Phd2 does have 
activity towards HIF-α in these tissues but neither proving HIF-dependent nor 
ruling out HIF-independent components of the Phd2-null phenotype.   
 Tissue-specific and combinatorial mouse models of VHL Disease.  As 
discussed above, Vhl-null germline and mosaic models are characterized by 
defects in placental vascularization, age- and genetic background-dependent 
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hepatic angiomas, and a lack of renal cysts and RCC.  Tissue-specific promoter-
driven cre recombinase systems have been used variously to determine cell type 
of origin, dependence on HIF-α, and to enhance or reveal VHL Disease-
associated phenotypes. 
 Cell-of-origin for Vhl-dependent placental labyrinth phenotype.   The 
requirement for Vhl in the embryonic vasculature was investigated using a Tie2-
cre transgenic mouse line directing recombination in endothelial cells(132).  Tie2-
cre;Vhlf/f and Tie2-cre;Vhlf/f;Hif1af/f died in utero at E12.5-13.5, slightly later than 
germline Vhl-null mice but with an identical defect in labyrinthine vascularization.  
Use of a Mox2-cre transgenic mouse line, in which recombination is completely 
excluded from extra-embryonic and trophoblast lineages, recapitulated the Tie2-
cre results, indicating that the requirement for Vhl in labyrinthine vascularization 
resides in the embryonic allantoic endothelium rather than the trophoblast 
compartment.  In addition to placental defects, Tie2-cre;Vhlf/f and Tie2-
cre;Vhlf/f;Hif1af/f embryos were associated with several other vascular defects, 
including gross embryonic hemorrhage, collapse of endocardial vessels, and 
dilation and decreased branching and network complexity in the yolk sac and 
cephalic and dorsal regions of the embryo. 
 Cell-of-origin and HIF-dependence of Vhl hepatic angiomas.  Given that 
VHL Disease-associated hemangioblastomas arise secondary to VHL LOH in the 
stromal compartment (35), Vhl-associated hepatic angiomas were postulated to 
originate from hepatocytes.   Two groups analyzed the repercussions of Vhl loss 
in the hepatocyte compartment using an albumin-cre transgenic mouse line in 
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which directs high-efficiency (60-80%), hepatocyte-specific recombination(111, 
133).  Both groups observed that Albumin-cre;Vhlf/f mice were runted and died at 
6-12 weeks with gross hepatomegaly and severe hepatic steatosis, angiectasis 
or microscopic angiomas, and endothelial cell proliferation(111, 133).  Albumin-
cre;Vhlf/f;Hif1af/f mice developed an identical phenotype, but the livers of Albumin-
cre;Vhlf/f;Arntf/f mice were grossly and microscopically normal(133). 
 In a complementary approach, Rankin et al. utilized a PEPCK-cre 
transgenic mouse line activity in the kidney and periportal hepatocytes (20-30% 
efficiency)(134).  In contrast to Albumin-cre;Vhlf/f mice, PEPCK-cre;Vhlf/f mice 
survived past 15 months and developed high penetrance macroscopic or 
cavernous hemangiomas (35%) and microscopic heptic angiectasis, steatosis, 
and endothelial cell proliferation (80%) at age six months or older.  PEPCK-
cre;Vhlf/f;Hif1af/f mice developed identical macroscopic and microscopic hepatic 
vascular lesions with similar penetrance(133, 134).  Furthermore, both Arnt (133) 
and Hif2a (134) knock-out rescued the hepatocytic Vhl-dependent hepatic 
angioma phenotype, confirming that the hepatic angioma phenotype observed in 
germline and mosaic Vhl-null animals arises from Vhl loss in the hepatocyte 
compartment and is dependent on HIF-2α. 
 A third approach solidified the connection between hepatocytic HIF-2α 
stabilization and hepatic angioma formation.  Kim et al. studied the effects of 
stabilized HIF-1α and/or HIF-2α in hepatocytes using Albumin-cre and 
conditional loxP-stop-loxP (lsl) HIF-α double proline?alanine (dPA) mutants 
alleles knocked-in to the ubiquitously-expressed Rosa26 locus (135).  Cre 
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recombinase activity results in recombination between loxP sites, excising the 
stop cassette and permitting expression of the HIF-α dPA genes.  HIF-1α dPA 
and HIF-2α lack the prolyl residues required for recognition by pVhl and are 
therefore consitutively stable.  Similarly to Albumin-cre;Vhlf/f mice, Albumin-
cre;lsl-Hif1a-dPA;lsl-Hif2a-dPA died at 6-8 weeks with hepatomegaly and 
microscopic hepatic angiomas and steatosis.  Albumin-cre;lsl-Hif2a-dPA mice 
likewise died at 6-8 weeks with hepatomegaly and recapitulated the hepatic 
vascular phenotype.  The livers of Albumin-cre;lsl-Hif1a-dPA mice were grossly 
normal and displayed minimal microscopic evidence of hepatic steatosis and no 
vascular lesions.  These experiments show that hepatocytic HIF-2α stabilization 
is both necessary and sufficient for the formation of hepatic angiomas in mice. 
 Enhancement and HIF-dependence of Vhl renal cyst formation.  Though 
approximately 60% of VHL Disease individuals develop renal cysts, germline 
Vhl+/- mice only rarely develop renal cysts (~3%)(111).  The cell type of origin for 
VHL Disease-associated cysts is unknown, but evidence supporting both the 
proximal and distal tubule epithelium exists.  Rankin et al. investigated the loss of 
Vhl in the proximal renal tubule using the same PEPCK-cre system discussed 
above (136).  PEPCK-cre recombinase displays activity in the renal cortex and 
outer medulla, specifically in the proximal tubule epithelium, and in periportal 
hepatocytes.  The kidneys of PEPCK-cre;Vhlf/f mice aged to <12 months were 
microscopically normal, but the kidneys of 12-25 month old PEPCK-cre;Vhlf/f mice 
contained macroscopic (18%) and microscopic tubular (25%) and glomerular 
(35%) renal cysts.  Glomerular renal cysts are not a feature of human VHL 
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Disease.  Using immunohistochemical analysis, the epithelial cells lining the 
tubular microcysts were discovered to express markers of the distal tubule (55% 
of cysts) and de-differentiation (vimentin, 35% of cysts) but not of the proximal 
tubule (<5% of cysts).  These marker studies suggest that PEPCK-cre has 
undetectable or rare activity in the distal tubule or that proximal tubule-derived 
cystic epithelial cells undergo de- or trans-differentiation.  PEPCK-
cre;Vhlf/f;Hif1af/f mice developed renal macrocysts and microcysts with similar 
appearance and penetrance.  PEPCK-cre;Vhlf/f;Arntf/f mice did not develop renal 
cysts, suggesting a dependence on HIF-2α.  
 Though a dramatic improvement over germline Vhl+/- mice, the modest 
penetrance and delayed age-of-onset for renal cysts in the PEPCK-cre;Vhlf/f 
model suggests that additional genetic events are required to make a Vhl-
initiated renal cyst.  Given that human ccRCC tumors display reduced expression 
or loss of Pten or activation of PI3K or AKT(137-139), Frew et al. studied the 
combination of Vhl and Pten loss using the distal tubule-specific Ksp1.3-cre 
recombinase system(140).  Ksp1.3-cre;Vhlf/f mice developed fully penetrant 
hydronephrosis, and Ksp1.3-cre;Ptenf/f mice developed uroepithelial hyperplasia 
and hypertrophy in the renal pelvis, ureters, and bladder.  In addition to 
hydronephrosis and enhanced uroepitheial hyperplasia, 100% of double Ksp1.3-
cre;Vhlf/f;Ptenf/f mice aged 6 weeks – 6 months (n=14) developed renal cysts.  
Microscopically, the renal cysts displayed clear cell histology and predominantly 
simple epithelium.  Atypical papillary changes were observed in 8% of cysts.  
Immunohistochemical analysis showed that the renal cyst epithelium expressed 
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markers of the distal tubule and collecting duct but not the proximal tubule.  
Ksp1.3-Vhlf/f;Ptenf/f renal cysts also displayed activating phosphorylation of Akt 
and Erk enhanced relative to Ksp1.3-Vhlf/f mice based on both 
immunohistochemical analysis and immunoblot analysis from whole-kidney 
lysates.  These studies provide evidence that Vhl-initiated renal cysts arise from 
the distal tubular epithelium, are HIF-2α-dependent, and require additional 
genetic events. 
 A gene replacement model of Chuvash Polycythemia.  Taking advantage 
of the genotype-phenotype correlations in VHL Disease, Hickey et al. recently 
published a gene replacement mouse model of human Chuvash Polycythemia 
(112).  Humans homozygous for the R200W VHL mutation develop Chuvash 
Polycythemia, a benign polycythemia characterized by elevated hematocrit and 
hemoglobin levels, elevated serum Vegf and Epo, and thrombotic events(52-54).  
Mice homozygous for the Chuvash Polycythemia mutation (VhlR/R) are viable.  
VhlR/R mice gradually developed signs of polycythemia, including an age-
dependent increase in hematocrit (to 55% by 26 weeks) accompanied by 
elevated red and white blood cell counts and hemoglobin levels.  The 
erythrocytosis present in VhlR/R mice was associated with elevated Epo levels in 
the serum and kidney but not the liver.  VhlR/R bone marrow was histologically 
normal, but the spleen showed evidence of extra-medullary erythropoiesis, 
including expansion of the red pulp with erythroid precursors, and an increased 
megakaryocyte population.  VhlR/R mice displayed no evidence of tumor 
predisposition.   
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VHL and the Primary Cilium Hypothesis 
 Structure and function of the primary cilium.  The primary cilium is a single 
apical extension of the cell membrane (reviewed in (102, 103)).  The non-motile 
primary cilum acts like an antenna, tranducing molecular and sensory signals 
from the extracellular space.  The primary cilium consists of microtubules in a 
9+0 arrangement arising from the basal body or centriole.  Most quiescent (G0) 
cells have a primary cilum.  Upon entry into the cell cycle, the primary cilium is 
resorbed and the basal body acts as the microtubule organizing center (MTOC) 
for mitosis.  Because the primary cilium does not contain ribosomes, all proteins 
required for structure and function must be transported from the cytoplasm by 
intra-flagellar transport (IFT) with molecular motors.  Anterograde IFT proceeds 
by the action of the molecular motor kinesin-2, while retrograde IFT utilizes 
dynein-1b.The primary cilia of renal tubular epithelial cells extend into the tubular 
lumen and function as mechanosensors of urinary flow. 
 The Ciliary Hypothesis.  According to the ciliary hypothesis, mutation or 
loss of genes required for primary cilium structure or function predisposes to 
renal cyst formation (141).  Several inherited diseases featuring renal cyst 
formation have been linked to the primary cilium , including both autosomal 
dominant (142) and recessive (143) forms of Polycystic Kidney Disease and 
Bardet-Biedl Syndrome (144-146).   
 VHL and the Primary Cilium.  VHL-deficient RCC-derived cells are only 
sparsely ciliated in culture, but transgenic rescue with wild-type VHL restores 
primary cilium prevalence(147).  In primary cells such as MEFs, Vhl loss is 
 34 
 
insufficient to lose cilia, indicating that Vhl  is dispensible for primary cilium 
formation.  Vhl-deficient MEFs lose their cilia, however, in the context of 
physiological (ie, by growth factor or serum stimulation) or pharmacological 
GSK3β inhibition or deficiency, confirming a role for pVHL in primary cilium 
maintenance(104).  Phosphorylation of serine 72, likely by casein kinase (CK)-1, 
primes VHL30 for phosphorylation on serine 68 by GSK3β.  Phosphorylated 
VHL30 retains the capacity to bind microtubule but cannot stabilize cytoplasmic 
microtubules or maintain the primary cilium (105).  pVHL mutants defective for 
cytoplasmic microtubule binding cannot maintain the primary cilium, suggesting 
that the two functions are intimately linked (104).  These in vitro studies support a 
model in which GSK3β has both VHL-dependent and VHL-independent functions 
in maintaining the primary cilium.  Active GSK3β independently maintains the 
primary cilium and inactivates the microtubule stabilizing function of VHL30 via 
S68 phosphorylation.  In conditions when GSK3β is inactive or deficient, 
however, unphosphorylated VHL30 takes over responsibility for primary cilium 
maintenance(104).  VHL deficiency or loss, then, would be predicted to sensitize 
cells to loss of the primary cilium.   
 Supporting the idea that VHL loss alone is insufficient for renal cyst 
formation, VHL Disease-associated renal cysts (n=33) display a three-fold 
reduction in ciliation and are associated with VHL deficiency (approximated by 
expression of the HIF target gene CA9) and inactive (phospho-) GSK3β, but only 
46 out of 303 VHL-deficient single cells were concomitantly positive for displayed 
inactivated GSK3β (104).  Sporadic ccRCC tumors (n=20) also display drastically 
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reduced ciliation (7.5%) relative to normal renal tubular epithelium (83.7%), and a 
subset (5/20) additionally display positivity for phospho-Ser9 GSK3β (148). 
 Deficiency in PTEN activity would be predicted to increase signaling 
through AKT, which in turn phosphorylates and inactivates GSK3β (149).  
Combination of VHL loss and PTEN loss, then, would be predicted to confer 
predisposition to renal cysts.  In fact, distal tubule inactivation of both Vhl and 
Pten, but neither singly, results in a fully-penetrant renal cyst phenotype (140).  
While wild-type, single Vhl- or Pten-deficient, and morphologically normal double 
Vhl- and Pten-deficient distal tubules were 80-90% ciliated, cystic double Vhl- 
and Pten-deficient distal tubules were only 30% ciliated.  In vitro MEF cultures 
derived from single and double Vhl- and Pten-deficient mice indicated that 
primary cilium loss in double mutants was mTOR-independent but both AKT- and 
ERK/MEK-dependent, the activation of the latter pathways most likely due to 
autocrine or paracrine growth factor stimulation resulting from HIF-α stabilization.   
 Indeed, while Vhl single kidneys displayed mild activation of AKT and 
ERK1/2 and inactivation of GSK3β, the addition of Pten loss markedly enhanced 
both AKT and ERK activation and GSK3β inactivation.  Also, in addition to 
uniform inactivation of GSK3β, 25/33 human VHL Disease renal cysts 
additionally displayed ERK1/2 activation(140).  Altogether, current data suggests 
that VHL Disease- and sporadic ccRCC-associated renal cysts result from 
primary cilium loss due to the combined loss of VHL function and signaling 
through AKT and ERK/MEK.    
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HIF and Renal Tumorigenesis 
 Regulation of HIF-α translation.  HIF-1α and HIF-2α are constitutively and 
ubiquitously transcribed but are highly regulated at the level of translation, 
stability, and transcriptional activity.  Normoxic translation of HIF-1α and HIF-2α 
mRNA is enhanced by activation of mammalian target of rapamycin (mTOR) 
kinase activity.   
The mTOR pathway ties protein translation to nutrient availability and 
growth factor signaling (reviewed in (150, 151)).  The serine/threonine kinase 
mTOR assembles into two distinct complexes, mTORC1 and mTORC2, with 
distinct targets.  mTORC1 contains mTOR, raptor (152), mLST8, and PRAS40 
and directs phosphorylation of the substrates p70S6K and 4EBP1 (153).  
mTORC1 phosphorylation activates p70S6K (154), resulting in the 
phosphorylation of the 40S ribosomal subunit S6 and thereby promoting 
translation of ribosomal and other pyrimidine tract-containing RNAs (155).  
mTORC1-phosphorylated 4EBP1 results dissociates from eIF4E, localized at the 
5’ end of select mRNAs.  Released from 4EBP1, eIF4E is free to promote 
translational initiation of genes involved in cell proliferation including HIF-α, cyclin 
D1, c-myc, and VEGF(156, 157).  mTORC2 consists of mTOR, rictor, protor, and 
sin1 and phosphorylates AKT on Ser473, contributing to AKT activation.  
 mTORC1 activity is activated by Rheb (158), a small G protein, the activity 
of which is in turn inhibited by the GTPase activity of TSC2 in complex with 
TSC1(159-161).  TSC1/2 integrates nutrient and growth factor signaling to direct 
appropriate mTOR activity.  Conditions of energy deficiency (decreased 
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ATP:AMP ratio) activate AMP kinase (AMPK) (162).  Activated AMPK 
phosphorylates and activates TSC2, resulting in inhibition of mTORC1 activity 
and repression of translation(159-161).  In contrast, growth factor signaling via 
receptor tyrosine kinases activates PI3K, responsible for phosphorylating PIP2 to 
generate PIP3 in a reaction antagonized by PTEN activity.  The resulting PIP3 
activates PDK phosphorylation and activation of AKT(163), and activated AKT 
directs inhibitory phosphorylation of TSC2(164, 165), effectively relieving 
mTORC1 inhibition.  mTORC2 may be negatively regulated by Rheb, which 
would tend to shut down the feedback inhibition generated by mTORC2-
mediated activating phosphorylation of AKT(166). 
 Regulation of HIF-α stability.  HIF-α stability is primarily oxygen-
dependent.  In the presence of oxygen, the HIF prolyl hydroxylases (PHD) 1, 2, 
and 3 (74, 126, 127, 129), target two specific prolyl residues in the HIF-1α 
(residues 402 and 564) and HIF-2α (residues 405 and 531) oxygen-dependent 
degradation domains (ODDD) for hydroxylation(71, 72, 128, 130).  The PHD 
enzymes, together with the co-factors Fe++ and ascorbate, utilizes the substrates 
molecular oxygen (O2) and 2-oxoglutarate (2-OG) to convert prolyl residues to 
hydroxyprolyl residues, generating CO2 and succinate as by-products(167).  HIF-
α hydroxyprolyl residues are recognized and bound by the pVHL β domain, 
resulting in HIF-α ubiquitylation by the VBC ubiquitin ligase complex and 
degradation by the 26S proteasome(73, 75).  The Michaelis constant (KM) of the 
PHD enzymes for O2 is approximately 100 µM(168, 169), whereas most tissues 
achieve at most 10-30 µM O2.  As a result, PHD enzymatic activity is exquisitely 
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sensitive to changes in O2 tension.  Under anoxic conditions, PHD is inactive and 
HIF-α prolyl residues escape hydroxylation and recognition by pVHL.  PHD2 is 
thought to be the primary HIF-α hydroxylase(170-172).  HIF-α is also stabilized in 
an oxygen-independent manner by its association with the chaperone protein 
HSP90(173, 174). 
 Regulation of HIF-α transcriptional activity.  The C-terminal activation 
domain (CTAD) directs HIF-1α and HIF-2α transcriptional activation.  The CTAD 
is regulated in an oxygen-dependent manner analogous to the regulation of the 
HIF-α ODDD.  Factor inhibiting HIF (FIH), an Fe(II)- and 2-OG-dependent 
dioxygenase related to the PHD enzymes, catalyzes the hydroxylation of a single 
asparaginyl residue in the HIF-α CTAD (residue 803 in HIF-1α and 851 in HIF-
2α)(175-177).  The asparaginyl hydroxylation reaction requires Fe++ and 
ascorbate as co-factors, utilizes O2 and 2-OG as substrates, and generates CO2 
and succinate as by-products.  Similar to PHD, the KM of FIH for O2 (~90 µM) far 
exceeds physiological oxygen levels(178), making FIH likewise very sensitive to 
slight changes in oxygen tension.  Asparaginyl hydroxylation prevents the direct 
association of HIF-α CTAD with the transcriptional co-activators CBP and p300 
(176) and the recruitment of additional co-activators(179).  As a result of ODDD 
and CTAD hydroxylation, HIF-α subunits are both highly unstable (t1/2 ~5 
minutes(180)) and transcriptionally inactive under normal oxygen conditions. 
Pseudohypoxia in renal tumorigenesis syndromes.  In order to determine 
whether HIF-α stabilization is a common early molecular event in renal 
tumorigenesis, small renal cortical tumors (<2.0 cm in greatest diameter) from 
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patients with the inherited renal tumor predisposition syndromes Birt-Hogg-Dube 
(BHD), Hereditary Papillary Renal Cancer (HPRC), and VHL Disease (n=12 for 
each) were analyzed for HIF-1α and HIF-2α (181).  As expected, VHL ccRCC 
tumors uniformly expressed HIF-2α and 10/12 additionally expressed HIF-1α.  
BHD chromophobe and hybrid chromophobe/oncocytic RCC tumors also strongly 
and uniformly expressed HIF-2α, with 6/12 additionally and more weakly 
expressing HIF-1α.  Fifty percent of HPRC Type II papillary RCC tumors 
expressed HIF-2α, half of which expressed HIF-1α as well.  Given the small size 
of these tumors, HIF-1α and HIF-2α stabilization in BHD and HPRC tumors is 
unlikely to reflect physiological hypoxia.  Indeed, increasing evidence, discussed 
below, suggests that the genetic events predisposing to renal tumorigenesis 
have molecular links to the translation and post-translational stability of HIF-α.  
The renal and extra-renal manifestations of each syndrome are summarized in 
Table 1.2.  
 Tuberous Sclerosis.  Tuberous sclerosis is an autosomal dominant 
disease caused by germline mutations in TSC2 (encoding tuberin) and TSC1 
(15-30% of families, encoding hamartin) with an incidence of 1:6000 live births 
(reviewed in (182)).  TSC1-associated tuberous sclerosis tends to have a milder 
clinical course than TSC2-associated tuberous sclerosis(183-186).  The defining 
manifestation of tuberous sclerosis is the development of benign tumors 
(hamartomas or tubers) in multiple tissues.  Tuberous sclerosis patients are also 
afflicted with renal angiomyolipomas (80%)(187), cysts (53%), and rarely ccRCC 
(2-3%)(188, 189). 
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 The Eker rat model of renal adenoma features a spontaneous retroviral 
insertion in the rat TSC2 gene(190, 191).  Eker rats develop renal cysts, papillary 
cystadenomas, and solid adenomas with high penetrance.  Tsc2+/- mice also 
develop high-penetrance papillary cystadenoma (>95% at 14 weeks – 6 
months)(192).  Two different murine Tsc1 models displayed drastically different, 
partly genetic background-dependent, phenotypes.  The renal phenotype of 
Tsc1+/- mice ranged from altered tubules at 9-12 months on a mixed 
129SvJ/C57BL/6 background (193) to fully penetrant microscopic cysts, 
cystadenomas, and frank carcinoma with lung metastases on a Balb/c 
background by 15-18 months (194).  Like Vhl+/- mice, both Tsc1+/- and Tsc2+/- 
mice develop hepatic angiomas (20-80% at 15-18 months)(192-194).   
Tuberous sclerosis has a clear link to HIF-α – as described in detail, TSC1 
and TSC2 participate in the inhibition of mTOR.  Loss of function in either TSC1 
or TSC2, then, would be predicted to release mTOR from inhibition and enhance 
translation of HIF-α transcripts.  Eker-derived renal tumor cell lines (Tsc2-/-) and 
renal tumors over-express HIF-2α but not HIF-1α and over-express the joint HIF 
target gene VEGF.  Over-expression of HIF-1α and VEGF in Tsc2-/- murine 
embryonic fibroblasts (MEF) was rescued by rapamycin, indicating mTOR-
dependence(195).  
 Birt-Hogg-Dube Syndrome.  Birt-Hogg-Dube Syndrome (BHDS) is an 
autosomal dominant disease associated with germline mutations in the BHD 
tumor suppressor gene located at 17p11.2(196).  BHD mutations are almost 
exclusively frameshift and nonsense mutations predicted to result in C-terminal 
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truncation of the encoded protein, folliculin (FLCN)(196, 197).  The defining 
clinical feature of BHDS is fibrofolliculoma (95%) and other cutaneous lesions.  
BHDS patients also develop lung cysts (84%) with spontaneous pneumothorax 
(38%) and kidney tumors (34%).  While no specific genotype-phenotype 
correlations have been proven, RCC is present in 57% of BHDS individuals with 
family histories and only 23% of BHDS individuals without a family history of 
RCC(197).  The diverse histologies of BHDS-associated renal tumors include 
hybrid oncocytic/chromophobe RCC (50%), chromophobe RCC (34%), ccRCC 
(9%), oncocytoma (5%), and papillary RCC (2%)(198). 
 The Nihon rat model of spontaneous RCC features a frameshift mutation 
in the rat BHD gene.  Nihon rats develop ccRCC with complete penetrance by six 
months (199).  In a germline mouse model, 45% and 8% of Bhd+/- mice had 
developed oncocytic renal cysts and oncocytoma or chromophobe RCC, 
respectively (200).  In two independent models, loss of Bhd in the distal tubule 
(Ksp1.3-cre) resulted in death at three weeks from kidney failure, associated with 
gross bilateral polycystic kidneys and microscopic tubular dilatation (201, 202), 
hyperplasia, and cystic RCC(202) but no solid RCC. 
   Death due to renal failure was delayed in distal tubule Bhd-deficient mice 
by treatment with rapamycin (201, 202), and cystic Bhdd/d kidneys displayed 
enhanced phosphorylated, activated Akt, mTOR, and S6 levels relative to control 
kidneys.  Furthermore, human BHD-associated (201) and sporadic (203) 
chromophobe and hybrid oncocytic/chromophobe RCC tumors display a mild 
increase in mTOR phosphorylation and activation relative to adjacent normal 
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tissue.  BHD deficiency is clearly associated with mTOR with AKT/mTOR 
pathway activity, but the mechanism of such influence is still unclear.  FLCN has 
been shown to interact with folliculin-interacting proteins (FNIP)1 (204) and/or 
FNIP2 (205, 206) directly via its C-terminus, and FNIP1/2 in turn binds to 
phosphorylated AMPK (204-206).  As the majority of human BHDS mutations 
result in C-terminal truncations of FLCN which would be predicted to disrupt this 
interaction(197) and because both FNIP1/2 and FLCN are phosphorylated in an 
AMPK- and mTOR-dependent manner, the FLCN-FNIP1/2-AMPK interaction is 
likely to biologically significant.  The influence of BHD status on mTOR activity, 
however, is highly context-dependent.  Genetic knock-down of BHD, FNIP1, or 
FNIP2 by siRNA in HeLa cells, for example, resulted in decreased 
phosphorylation and activation of mTOR (206).  In contrast, inhibition of mTOR 
signaling by exogenous AMPK stimulation or rapamycin treatment or activation of 
mTOR by serum stimulation were unaffected by BHD status, while inhibition of 
mTOR activity by serum starvation was impaired and by amino acid deprivation 
was enhanced in a BHD-null ccRCC cell line relative to its BHD-rescued 
counterpart (204).  Over-expression of HIF-α in BHDS renal tumors, then, may 
result from FLCN function upstream or downstream of mTOR, depending on the 
tumor’s genetic history and microenviroment. 
 Hereditary Papillary Renal Carcinoma.  Hereditary Papillary Renal 
Carcinoma (HPRC) is an autosomal dominant disorder with incomplete 
penetrance resulting from germline activating mutations in the MET proto-
oncogene (7q)(207, 208).  MET is the receptor tyrosine kinase (RTK) for 
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hepatocyte growth factor/scatter factor (HGF/SF)(209) and transduces signals for 
cell growth and motility via several signaling cascades, including MAPK/ERK and 
PI3K/AKT(210).  HPRC MET mutations are typically missense mutations in the 
MET TK domain conferring constitutive phosphorylation and activation (10, 11, 
207).  HPRC individuals are at risk for multiple, bilateral Type I papillary RCC 
tumors but are not predisposed to any other benign or malignant neoplasms 
(211).    Both HPRC-associated (10) and sporadic (12, 212) papillary RCC 
tumors commonly feature trisomy of chromosome 7, with selective duplication of 
the chromosome carrying the mutant MET allele.   
   A panel of mice expressing gene replacement alleles representative of 
several human HPRC MET missense mutations developed sarcomas, 
lymphomas, and rare carcinomas with genotype-specific associations (213).  
None of the Met mutant mice developed renal carcinoma.  Cytogenetic analysis 
of mutant Met tumors, however, indicated that 97% contained cells with trisomy 
and 30% contained cells with tetrasomy for Chromosome 6 (the locus for murine 
Met).  Less than 2% of cells in normal tissues displayed Chromosome 6 trisomy.  
Fifty percent of mutant Met tumors also contained cells with specific amplification 
of the Met locus, though such events were less frequent than whole-chromosome 
duplication.  Despite being unable to recapitulate the tissue-specificity of human 
mutant MET activity, the mouse model validates MET amplification as a critical 
event in tumorigenesis. 
 No studies have directly addressed the mechanism by which oncogenic 
MET might directly increase HIF-α expression.  Constitutively active MET may 
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signal through PI3K, resulting in AKT activation, TSC1/2 inhibition, and mTOR 
activation with an outcome of increased HIF-α translation.  The possibility 
remains that HIF-α stabilization may be an independent event in the history of 
HPRC-associated and sporadic papillary RCC tumors.  Interestingly, evidence 
exists linking VHL loss to MET activity (214).  VHL-null RCC cell lines over-
express phosphorylated, activated MET relative to normal renal proximal tubule 
epithelial cells (RPTEC).  Suppression of MET signaling required both wild-type 
VHL and cell-cell contact. 
 Hereditary Leiomyomatosis and Renal Cell Cancer and Hereditary 
Paraganglioma.  Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is 
associated with germline mutations in the fumarate hydratase (FH) gene (215, 
216).  Fumarate hydratase catalyzes the conversion of fumarate to malate in the 
Krebs Cycle.  Fibroblast cell lines derived from the cutaneous leiomyomas of 
HLRCC patients (FHm/m) display a near-complete reduction in fumarate 
hydratase enzymatic activity (217).   Cutaneous leimoyomas (100%) and uterine 
leiomyomas (98% of females), or fibroids, are highly penetrant features of 
HLRCC(216).  Approximately 1/3rd of HLRCC individuals develop unilateral, 
solitary Type 2 papillary RCC or collecting duct carcinoma (CDC), often with an 
aggressive clinical course(218).  HLRCC-associated Type 2 papillary RCC 
tumors display HIF-α over-expression (HIF-1α > HIF-2α) (217, 219).   
 Distal tubule-specific (Ksp1.3-Cre) deletion of fumarate hydratase 1 (Fh1) 
in mice confers death from renal failure with complete penetrance at 8-15 
months(220).  Renal failure in Ksp1.3-Cre;Fh1f/f mice is associated with 
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development of bilateral renal macrocysts and over-expression of both HIF-1α 
and HIF-2α in the cyst epithelial lining (in 50% and 25% of nuclei, respectively). 
 Germline mutations in succinate dehydrogenase (SDH) subunits B, C, and 
D, are associated with Hereditary Paraganglioma (HPGL) syndrome (221-223).  
The HPGL syndromes were originally described as predisposing to head and 
neck paragangliomas and adrenal and extra-adrenal pheochromocytomas.  
Somatic mutations in SDH are also common in sporadic pheochromocytomas 
and paragangliomas (224).  Recently, however, several families with germline 
SDHB mutations have been reported to develop early-onset RCC with (225, 226) 
or without (227) a family or personal history of paraganglioma or 
pheochromocytoma.  Succinate dehydrogenase functions in the Krebs cycle, 
converting succinate to fumarate, the substrate of fumarate dehydrogenase. 
 FH and SDHB mutations contribute to HIF-α stabilization by a novel 
mechanism: direct competitive inhibition of PHD activity.  As described above, 
hydroxylation of specific prolyl residues in the HIF-α ODDD utilizes prolyl, O2, 
and 2-OG as substrates to generate hydroxyprolyl, CO2, and succinate (167).  
SDH deficiency would be predicted to increase intracellular succinate levels, and 
FH deficiency would be predicted to increase both fumarate and, because the 
SDH reaction is reversible, succinate.  Metabolomic analysis of human disease 
tissues indicates that HLRCC-derived fibroids do indeed have elevated 
intracellular levels of both succinate and fumarate, while HPGL (SHDB)-derived 
paragangliomas have elevated intracellular levels of succinate alone (217).  
Suggesting that the association between the genetic lesion and metabolic profile 
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is a causative relationship, knock-down of FH (219) or SDHB (228, 229) in vitro 
results in intracellular fumarate or succinate accumulation, respectively,  and 
HIF-α stabilization (HIF-1α > HIF-2α).  Isaacs et al. confirmed that both succinate 
and fumarate are direct competitive inhibitors of 2-OG for PHD2 activity, resulting 
in reduced HIF-α ODDD prolyl hydroxylation and recognition by VHL.  
Interestingly, fumarate (Km = 2.6 µM) was shown to be a better inhibitor of PHD2 
activity than succinate (Km = 9 µM), possibly because the chemical structure of 
fumarate is similar to but more rigid than succinate (219).  As proof of concept, 
exogenous 2-OG treatment rescues PHD activity in cells with artificially elevated 
succinate (230) or fumarate (219) levels.  Though the HIF-α asparaginyl 
hydroxylation reaction catalyzed by FIH proceeds by a mechanism analogous to 
PHD-mediated prolyl hydroxylation, neither succinate nor fumarate were 
determined to inhibit FIH activity at physiologically-achievable intracellular 
concentrations (178). 
 The mechanisms by which each renal tumor predisposition syndrome 
affects HIF-α expression or stability is summarized in Figure 1.2. 
Treatment of Renal Cell Carcinoma 
Modified with permission from: Rathmell WK, Martz CA, and Rini B.  Renal cell 
carcinoma.  Current Opinion in Oncology 19(3): 234-40 (231). 
 Gene expression analysis of RCC.  The development of rational treatment 
strategies for renal tumors necessitates a nuanced understanding of the shared  
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and unique features of each RCC subtype.  In addition to studying the shared 
molecular biology of renal tumors, as discussed above, the study of mixed RCC 
tumors by gene expression profiling has yielded remarkable insight into the 
biologies of individual RCC subtypes.  Yang et al. found that histopathological 
review alone could not fully and accurately describe a chromophobe-oncocytoma 
hybrid and a high-grade clear cell tumor with an oncocytomatous component, but 
adding gene expression array analyses aided identification of these mixed 
tumors (232).  Jones et al. studied the genetic histories of RCC tumors with both 
clear cell and sarcomatoid components.  Clear cell and sarcomatoid components 
displayed identical X-inactivation patterns but different patterns of tumor 
suppressor loss, pointing towards origin from a common cell with subsequent 
genetic divergence (233).  Finally, Skubitz et al. found clinically-relevant 
molecular and metabolic heterogeneity even within a group of morphologically 
homogeneous clear cell RCC tumors(234).   
 Even tumors with similar morphologies exhibit molecular heterogeneity.  In 
a small study of sixteen RCC tumors classified as clear cell in histology, gene 
expression array analysis separated the ccRCC tumors into ccRCC-A and –B 
groups with different clinical and molecular profiles(234).  Type B tumors tended 
to display higher nuclear grade and higher clinical stage, supporting a more 
clinically aggressive phenotype, in comparison to Type A tumors.  Tumors with 
sarcomatoid features, historically associated with poor prognosis, grouped in the 
Type B cluster, and previously identified gene sets predictive of clinical outcome 
sorted the tumors into similar groups.  The gene expression array analysis also 
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provided insight into underlying differences in tumor biology between Type A and 
Type B ccRCC.  Type B tumors over-expressed extra-cellular matrix genes, 
including fibronectin and collagens, and adhesion genes, including NCAM and 
CD44, while Type B ccRCC tumors over-expressed genes in the glycolytic 
pathway.   
 DNA microarray analysis of a much larger set of 177 ccRCC tumor 
samples separated ccRCC tumors into five distinct subgroups (235) with 
prognostic significance.  Subgroups one and two were very molecularly similar, 
differing mainly in the transcriptional regulator profiles, and displayed the best 
long-term survival after radical nephrectomy.  Subgroup three tumors displayed 
relatively higher expression of proliferation-associated and collagen genes but 
not hypoxia-regulated genes and were associated with the worst long-term 
survival after surgery.  Subgroup four tumors, featuring granular cytoplasm, were 
associated with over-expression of characteristic chromophobe RCC and 
oncocytic genes including c-KIT and mitochondrial genes.  Finally, subgroup five 
tumors displayed decreased expression of membrane transporters and a subset 
over-expressed collagen genes.  Tumor subgroup predicted long-term survival 
independently of grade, stage, or performance status, indicating that the 
subgroups reflect clinically-relevant and fundamental differences in tumor 
biology.  These studies validate searches for shared RCC initiation pathways but 
simultaneously urge further study of the molecular changes responsible for 
specifying RCC subtype and determining clinical behavior and response to 
treatment.  
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 Targeted Therapy.  Recent years have witnessed a significant expansion 
of therapeutic options in metastatic RCC through the application of therapy 
targeted at specific proteins and cellular receptors, most notably directed against 
various components of the VEGF pathway. Data regarding several of these 
approaches has been updated recently (summarized in Table 1.3). A randomized 
phase II trial of bevacizumab monotherapy versus bevacizumab plus erlotinib 
was conducted to determine the value of the combination regimen, and the 
results provide further insight into the benefit of this agent in metastatic RCC. 
One hundred three patients with metastatic RCC and no prior systemic therapy 
were randomized. Bevacizumab monotherapy had a 13% objective response 
rate and an 8.5 month progression-free survival (PFS) (236).  Of note, this trial 
failed to confirm a response rate or PFS advantage for combination 
bevacizumab/erlotinib therapy over bevacizumab monotherapy. This important 
data substantiates the benefit of bevacizumab in untreated RCC. The results also 
underscore the importance of randomized comparisons to determine the additive 
value of combinations over monotherapy.   
 Sunitinib is an oral inhibitor of VEGF and related receptors that was Food 
and Drug Administration (FDA) approved in January 2006 for the treatment of 
advanced RCC. The second of two phase II trials was published recently and 
contains a pooled analysis of patients on both phase II trials (237, 238).  These 
trials were conducted in cytokine-refractory, metastatic RCC patients and 
demonstrated a RECIST-defined overall response rate (investigator-assessed) of 
42%. The combined PFS was 8.2 months, and the median PFS of patients 
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Table 1.3. Summary of select phase II /III trials using targeted therapy in 
metastatic RCC*   
Agent  Trial design Results: PFS, ORR, OS Major toxicities 
 
Bevacizumab 
 
Phase II   
Randomized double-blind 
Cytokine-refractory 
Low or high dose 
bevacizumab vs. placebo 
n=116 
 
Phase II  
Randomized 
Previously untreated 
Bevacizumab/erlotinib vs. 
bevacizumab/placebo  
n=104 
 
 
PFS:4.8 months with high 
dose  
(vs. 2.5 months with 
placebo); p=0.0001 
 
 
 
PFS: 8.5 months with 
bevacizumab 
monotherapy (vs. 9.9 
months with combination; 
p=n.s.) 
ORR: 13% (vs.14% with 
bevacizumab + erlotinib) 
 
 
Hypertension, 
proteinuria 
 
 
 
 
 
Hypertension, 
rash, diarrhea, 
bleeding 
 
 
 
Sunitinib Phase II 
Two single arm trials 
n=63 and 106 
 
Phase III  
Randomized trial 
Previously untreated 
Sunitinib vs. IFN 
n=750 
 
PFS: 8.2 months,  
ORR:42% 
 
 
PFS:11 months (vs.5 
months with IFN); 
p<0.000001 
ORR: 31% (vs.6% with 
IFN) 
p<0.000001 
 
Fatigue, hand foot 
syndrome, 
diarrhea, 
cytopenia, 
mucocitis 
 
 
 
Temsirolimus Phase II 
Random assignment to 25, 
75 or 250 mg temsirolimus 
IV weekly 
n=111 
 
 
 
Phase III 
Randomized three arm: 
temsirolimus + IFN vs. IFN 
alone vs. temsirolimus 
alone 
n=626 
 
PFS: 5.8 months  
ORR: 7% 
 
 
 
 
 
 
PFS: 3.7 months for 
monotherapy arm (vs.1.9 
months for IFN α) 
OS: 10.9 months (vs. 7.3 
months for IFN); p=0.0069 
 
Rash, mucositis, 
asthenia, nausea 
hyperglycemia, 
hypo-
phosphatemia, 
anemia, hyper-
triglyceridemia 
 
Asthenia, anemia, 
dyspnea 
 
Everolimus 
 
Phase III 
Randomized double-blind 
RTK refractory 
Everolimus (10 mg oral qd, 
n=272) vs. placebo 
(n=138) 
PFS: 4 months (vs. 1.9 
months for placebo), 
p<0.0001 
ORR: 1% (vs. 0% for 
placebo) 
Stomatitis, rash, 
asthenia, diarrhea 
*Modified from Rathmell WK et al. 2007 (231) 
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achieving a PR was 14.8 months versus 7.9 months for patients with a best 
response of SD.  Toxicity in the combined analysis of these trials included 
fatigue/asthenia (all grades 28%; grade 3: 11%), hypertension (16%, 6%), 
diarrhea (20%, 3%), stomatitis (13%, 5%) and hand-foot syndrome (15%, 7%).  
Neutropenia was observed in 42% (grade 3 or 4 in 16%) but there were no cases 
of neutropenic fever or sepsis.  Five patients experienced a decline in cardiac 
ejection fraction as assessed by MUGA of 20% or more and to below the lower 
limit of normal, but no patient developed signs or symptoms of congestive heart 
failure. Baseline patient characteristics associated with response to sunitinib 
included a normal hemoglobin and ECOG performance status 0.  Additional data 
regarding the association of tumor response/shrinkage and clinical outcome as 
well as discovery of factors predictive of response to sunitinib and similar agents 
is needed. A subsequent randomized phase III trial in untreated, metastatic RCC 
patients (n=750) of sunitinib versus interferon alpha was also recently reported 
(20).  Sunitinib-treated patients demonstrated a significant advantage in objective 
response rate (31% versus 6%; p<000001) and PFS (11 months versus 5 
months; p<0.000001).  Data is not presently mature to permit assessment of 
possible overall survival benefit. 
 Temsirolimus is an inhibitor of mTOR, a molecule implicated in multiple 
tumor-promoting intracellular signaling pathways.  Regulation of mTOR pathway 
activation is mediated through a series of complex signaling interactions linking 
growth factor receptor signaling, PI3Kinase activation, and activation of the 
Akt/PKB pathway which dictates changes in cellular metabolism, coordinated 
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with alterations in cell growth, mitogenesis and susceptibility to apoptosis.  Akt 
causes mTOR activation via negative signals which disrupt the tonic inhibition of 
Rheb provided by the TSC1/TSC2 complex.  This signaling pathway was recently 
comprehensively reviewed by Plas and Thompson (239).  Mutations in either 
TSC1 or TSC2 cause constitutive activation of mTOR and subsequent enhanced 
translation of HIF-1α and increased susceptibility to the development of renal cell 
carcinoma (Figure 1.2).  
 Temisrolimus was initially tested in treatment-refractory, metastatic RCC 
randomized 111 patients to one of multiple dose levels (25 mg, 75 mg or 250 mg 
IV weekly). The overall response rate was 7%, with additional patients 
demonstrating minor responses. Retrospective assignment of risk criteria to 
patients in this study identified a poor-prognosis group (n=49). Temsirolimus-
treated patients in this poor-prognosis group had a median overall survival (OS) 
of 8.2 months compared to 4.9 months for historical control IFNA treated patients 
(240).  Additionally, a phase I trial investigated the safety of combination therapy 
with temsirolimus and IFNA and established the MTD to be temsirolimus 15 mg 
IV weekly and IFN 6 MU 3x/week, a dose which produced an objective partial 
response in 13% of patients (241). 
 A subsequent randomized phase III trial was conducted in patients with 
metastatic RCC and 3 or more adverse risk features as defined by existing 
prognostic schema (240, 242).  Patients were randomized equally to receive 
IFNA 18 MU 3x/week, temsirolimus 25 mg IV weekly or temsirolimus 15 mg IV 
weekly + IFNA 6 MU 3x/week. The primary study endpoint was OS and the study 
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was powered to compare each of the temsirolimus arms to the IFNA arm. 
Patients treated with temsirolimus had a statistically longer overall survival than 
IFNA monotherapy patients (10.9 months vs. 7.3 months, p=.0069) (17).   
 A second related mTOR inhibitor, everolimus (RAD001), was tested in a 
double-blind randomized Phase III trial in patients with metastatic RCC with a 
clear cell component who had progressed on the VEGF RTK inhibitors sunitinib 
and/or sorafenib(18).  Patients were randomized 2:1 to receive 10 mg oral 
everolimus daily plus best supportive care or placebo plus best supportive care.  
Treatment was administered in 28-day cycles until progression, death, 
unacceptable toxicity, or discontinuation.   Patients who developed documented 
progression on placebo therapy were unblinded and permitted to cross-over to 
the everolimus arm.  The primary endpoint for the study was progression-free 
survival (time from randomization to disease progression or any-cause death) as 
measured by RECIST criteria by blinded central review.  Secondary endpoints 
included OS and OR.  The trial was halted after the second interim analysis 
because its criterion of clinical significance, a 33% reduction in risk, had been 
reached.   
 Everolimus significantly prolonged PFS compared to placebo (HR 0.30, 
95% CI 0.22-0.44, p<0.0001).  The median PFS for patients randomized to 
receive everolimus was 4.0 months (95% CI 3.7-5.5), while the median PFS for 
patients randomized to receive placebo was 1.9 months (95% CI 1.8-1.9).  One 
percent (three patients, all PR) achieved objective response on everolimus 
treatment and none in the placebo group, indicating that the prolonged PFS 
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observed in patients randomized to receive everolimus therapy was due to 
disease stabilization rather than disease regression.  OS was not significantly 
different between patients randomized to receive everolimus and those 
randomized to receive placebo (median not reached versus 8.8 months, 
respectively).  Any difference in OS was likely blunted by the conjunction of 
intention-to-treat analysis and heavy cross-over from the placebo to the 
everolimus arms.  Based on these results, the FDA recently approved everolimus 
for the treatment of patients with advanced RCC who have failed on sunitinib or 
sorafenib.  Additional trials studying everolimus in the neoadjuvant setting and in 
combination therapy are currently underway.  The outcomes of the temsirolimus 
and everolimus clinical trials validate mTOR as a relevant therapeutic target in 
RCC, at least in a subset of patients with multiple adverse risk features.  
 It has become clear through further experience with targeted agents that 
the traditional methods to assess response and progression of disease 
employing CT scans and RECIST criteria may be inadequate. Some responding 
lesions may not change or even increase in size, but have a necrotic appearance 
to the center of the lesion consistent with an anti-tumor effect. Similarly, the 30% 
threshold of tumor burden shrinkage required for a RECIST-defined objective 
response is arbitrary and may not carry substantial weight in the evaluation of 
these agents. More precisely, lesser degrees of tumor shrinkage (1-29%) have 
been commonly observed with targeting agents and likely account for some of 
the PFS benefits observed in randomized trials. A recent publication adds to the 
literature regarding functional imaging of tumors for more precise evaluation of 
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drug effect (243).  Twenty-four patients with RCC underwent a dynamic contrast-
enhanced helical CT of the kidney prior to radical nephrectomy. Radiographic 
parameters of tumor enhancement were then compared to the histologic 
parameters of grade and microvessel density (MVD). Radiographic enhancement 
parameters were significantly correlated with MVD but not grade in this small 
series. This data supports that radiographic enhancement of RCC tumors is a 
reflection of the vascularity of RCC tumors and that this vascularity can 
potentially be quantified. The next step would then be to use these techniques to 
assess tumor vascularity pre- and post-VEGF targeted therapy to determine if 
these parameters can add value to standard radiographic assessments of tumor 
size. Further research in to functional imaging in RCC is sorely needed. 
 Combinations of targeted agents with each other or with cytokines are a 
recent area of investigation in metastatic RCC. Sorafenib and interferon have 
been combined in two separate single-arm phase II trials (19, 244).  These trials 
demonstrated objective response rates of 18% and 35%, perhaps owing to 
differences in enrollment criteria between these two studies, as the first study 
was limited to cancers with a clear cell component. Toxicity observed was typical 
of that observed with each single agent with a notable reduction in hand foot 
syndrome compared to historical sorafenib monotherapy data. The 
benefit/toxicity ratio of this combination regimen awaits further investigation. 
 Cytokine Therapy.  Cytokine therapy with IL-2 or IFN-α is of modest 
benefit in unselected populations. It would be unwise, however, to completely 
abandon this therapy given that metastatic RCC is still a fatal disease for the vast 
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majority of patients. Two strategies emerge for harnessing the benefit of 
cytokines in an era of active targeted therapy: patient selection and combination 
therapy. 
 An example of the potential value of using a molecular marker to select 
patients and also an example of combination therapy is a phase II trial of IFNA in 
combination with the cyclooxygenase-2 (COX-2) inhibitor celecoxib in patients 
with maximal COX-2 expression. A previous trial in unselected metastatic RCC 
patients demonstrated an enhanced response rate in the subgroup of patients 
with maximal COX-2 expression as assessed by immunohistochemical staining 
of primary RCC tumors (245).  This trial generated a hypothesis that COX-2 
inhibition in tumors with maximal COX-2 expression overcomes inherent 
immunosuppression and may enhance the clinical value of cytokines. A 
prospective trial of IFNA and celecoxib is thus ongoing in RCC patients with 
maximal COX-2 expression. In addition, two completed large phase III trials of 
interferon plus bevacizumab versus interferon alone are awaited and will define 
the activity of this combination regimen. 
 VHL and Clear Cell Renal Cell Carcinoma.  Both VHL Disease-associated 
and sporadic ccRCC progresses from renal cysts and dysplasia to local and 
invasive disease.  Mutation and LOH of VHL are evident in every stage of 
sporadic ccRCC, and VHL Disease kidneys display HIF target gene activation in 
morphologically single cells as well as cysts, dysplastic foci, and RCC(44), 
indicating that VHL loss is an early or initiating event in renal tumorigenesis(8).  
VHL patients develop many renal cysts with increasing age (44).  The average 
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age of diagnosis of ccRCC in VHL disease patients, however, is in the 4th to 5th 
decade of life (41), suggesting that genetic events in addition to VHL LOH are 
required for progression to RCC.  Evidence from mouse models suggests that 
signaling through the AKT and MEK/ERK pathways are required in the transition 
from VHL–initiated single cell to renal cyst(140), but the genetic and epigenetic 
events required for progression of VHL-initiated cysts to invasive RCC are poorly 
understood.  Renal tumors often display PTEN down-regulation(137, 139), 
resulting in increased AKT pathway activity(138).  Metastatic tumors can 
additionally harbor mutations in RB and TP53 and display increased myc and 
EGFR expression.  Unlike many smoking-associated tumors, however, RAS 
mutation is not a common feature of RCC(246). 
 The HIF axis is central to renal tumorigenesis: the gene products 
associated with renal tumor predisposition syndromes such as VHL Disease, 
Birt-Hogg-Dube Syndrome, Hereditary Papillary Renal Cancer, Hereditary 
Leiomyomatosis and Renal Cell Carcinoma, and Tuberous Sclerosis all impinge 
upon HIF-α translation or post-translational stability.  The VHL tumor suppressor 
gene is mutated or lost in both inherited clear cell RCC as part of VHL Disease 
and in sporadic ccRCC.  Though pVHL has a well-described role in the normoxic 
suppression of HIF-α, its contribution to primary cilium maintenance may also 
feature in renal tumorigenesis via the putative RCC precursor lesion, the renal 
cyst.  Mouse models of human VHL Disease suggest that one or more genetic or 
epigenetic lesions are required for progression of a VHL-initiated cell to a renal 
cyst and an unknown number of additional lesions are required to progress a 
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VHL-initiated renal cyst to renal adenocarcinoma, if the renal cyst is a precursor 
lesion at all.  In my dissertation work, I have taken advantage of the genotype-
phenotype correlations observed in human VHL Disease to study mutant pVHL 
ubiquitin ligase structure and function using molecular biology techniques and to 
model the in vitro and in vivo functions of a representative Type 2B VHL Disease 
mutant using a gene replacement mouse model. 
  
 
CHAPTER TWO 
VHL Type 2B mutations retain VBC complex form and function 
Modified from Hacker KE et al. 2008 (247). 
Abstract 
 Von Hippel-Lindau disease is characterized by a spectrum of 
hypervascular tumors, including renal cell carcinoma, hemangioblastoma, and 
pheochromocytoma, which occur with VHL genotype-specific differences in 
penetrance.  VHL loss causes a failure to regulate the hypoxia inducible factors 
(HIF-1α and HIF-2α), resulting in accumulation of both factors to high levels.  
Although HIF dysregulation is critical to VHL disease-associated renal 
tumorigenesis, increasing evidence points toward gradations of HIF 
dysregulation contributing to the degree of predisposition to renal cell carcinoma 
and other manifestations of the disease.  This investigation examined the ability 
of disease-specific VHL missense mutations to support the assembly of the VBC 
complex and to promote the ubiquitylation of HIF.  Our interaction analysis 
supported previous observations that VHL Type 2B mutations disrupt the 
interaction between pVHL and Elongin C but maintain partial regulation of HIF.  
We additionally demonstrated that Type 2B mutant pVHL forms a remnant VBC 
complex containing the active members ROC1 and Cullin-2 which retains the 
ability to ubiquitylate HIF-1α.
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Our results suggest that subtypes of VHL mutations support an intermediate level 
of HIF regulation via a remnant VBC complex.  These findings provide a 
mechanism for the graded HIF dysregulation and genetic predisposition for 
cancer development in VHL disease. 
Introduction 
 von Hippel-Lindau (VHL) disease is an autosomal dominant familial 
cancer syndrome caused by germline mutation or loss of the VHL tumor 
suppressor gene that affects approximately 1 in 36,000 individuals (248).  
Individuals with VHL disease develop an array of tumors, including clear cell 
renal cell carcinomas (ccRCC), cerebellar and retinal hemangioblastomas, and 
pheochromocytomas (248).  VHL disease is divided by genotype into subtypes 
which predict the spectrum of risk for development of VHL-associated lesions  
(48, 49, 249).  Type 1 VHL disease predisposes to the development of ccRCC 
and hemangioblastoma.  All patients with Type 2 VHL disease are at risk for 
pheochromocytoma.   Type 2A VHL disease is further characterized by high risk 
for hemangioblastoma, and Type 2B VHL disease is associated with high risk for 
both hemangioblastoma and RCC.  Type 2C VHL disease individuals exclusively 
develop pheochromocytoma (250).  Patients homozygous for the Arg200Trp 
(R200W) VHL mutation, located in the extreme C-terminal domain of the 213 
amino acid VHL protein (pVHL), develop Chuvash Polycythemia (52, 53).  
Biallelic inactivation of pVHL has also been reported in upwards of 90% of 
individuals with sporadic ccRCC (251).  Thus, a thorough understanding of wild-
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type and disease-associated mutant pVHL activities has potential to impact a 
broad spectrum of affected patients (248, 252, 253)  
 The VHL protein acts as the substrate recognition subunit of an E3 
ubiquitin ligase complex analogous in structure to the SCF complex.  The SCF 
and SCF-like complexes typically contain four subunits, including a RING finger 
protein (ROC1/Rbx1), a cullin protein (CUL/Cul), and two adaptor proteins linking 
the cullin to the substrate binding protein (254).  In the pVHL E3 complex (VBC),  
pVHL acts as the substrate binding protein and is responsible for the specificity 
of the complex-target interaction (255).  Human pVHL directly interacts with 
Elongin C, while Elongin B links pVHL-Elongin C to cullin 2 (CUL2)-ROC1 (55, 
58, 60).  The VBC complex serves as a platform through which the E2 ubiquitin-
conjugating enzyme, bound by CUL2-ROC1, and the pVHL-bound substrate are 
brought into proper positioning for ubiquitin transfer (254).  In the VBC complex, 
ROC1 functions to recruit the E2 enzyme and also promotes internal complex 
stability (60, 255).   
 The primary targets of the VBC complex are the hypoxia inducible factors, 
HIF-1α and HIF-2α.  The HIF factors direct the transcriptional response to 
hypoxia by activating the expression of genes involved in angiogenesis, cell 
proliferation, erythropoiesis, energy metabolism, and apoptosis (51, 63-65, 256, 
257).   
 Loss of the pVHL tumor suppressor, as occurs with Type 1 VHL 
mutations, is believed to promote renal tumorigenesis primarily through loss of 
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pVHL-mediated HIF regulation (258).  Correspondingly, Type 2C VHL missense 
mutations display fully intact regulation of HIF factors, consistent with the lack of 
conveyed risk for RCC development (100).  In the case of Type 2A and Type 2B 
VHL missense mutations, titrated degrees of HIF regulation appear to correlate 
with the subtype-specific risk of ccRCC (257, 259).  While the differing 
capabilities of VHL disease-associated mutants to regulate HIF have been 
explored (51, 100, 107, 257, 259), the mechanism of retained HIF regulation and 
the link between differing levels of HIF regulation and the clinical spectrum 
observed in VHL disease is not yet fully understood.  In this study, we re-
examined the effect of VHL missense mutations to disrupt the formation of the 
VBC complex, and demonstrate that characteristic Type 2B VHL mutations form 
a low-abundance VBC complex which retains the ability to ubiquitylate HIF-1α.   
Results 
Type 2B mutant pVHL proteins promote incomplete normoxic HIF-2α 
stabilization.  We have previously shown that human VHL mutations 
representative of Types 2A and 2B VHL disease impart an intermediate degree 
of HIF-2α regulation in a Vhl-null murine ES cell expression system (107).  In 
order to evaluate this trend in human RCC cells, 786-0 RCC-derived cells, known 
to lack pVHL expression and over-express HIF-2α, were reconstituted with 
expression vectors encoding wild-type or VHL disease-specific mutant VHL 
cDNA.   Individual clones expressing mutant pVHL comparable to wild-type 
levels were selected for subsequent experiments.  Figure 2.1A depicts a 
representative immunoblot for the expression of wild-type as well as RCC-  
 65 
 
 
 
Figure 2.1. VHL disease-associated mutations demonstrate a graded amount of 
HIF Regulation.  A. Anti-HA immunoblot for expression of HA-tagged human 
pVHL in transgenic 786-0 clones.  Whole-cell protein extracts were prepared 
from 786-0 clones deficient for VHL expression (Vector) or modestly expressing 
wild-type (WT) or missense (Y112H, R167Q) mutant HA-tagged human pVHL.  
B. Anti-HIF-2α immunoblot for HIF stabilization in 786-0 clones.  Whole-cell 
protein extracts were prepared from VHL-deficient 786-0 cells or WT or mutant 
HA-pVHL-rescued 786-0 cells incubated in the presence or absence of the 
hypoxia mimetic CoCl2 for 24 hours.  Ku80 immunoblot was used as a control for 
equal loading.    
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associated Type 2A (Y112H) and 2B (R167Q) mutant HA-tagged pVHL in 786-0 
RCC clones.   
 To study the ability of RCC-associated mutant pVHL to regulate HIF in 
786-0 cells, the hypoxia mimetic cobalt chloride (CoCl2) was used to simulate 
hypoxic conditions.  Cells were placed in either standard growth media or media 
supplemented with 100mM CoCl2for 24 hours followed by analysis of HIF-2α 
protein levels by immunoblot (Figure 2.1B).  VHL-null vector-only transfected 
cells (vector) failed to suppress HIF-2α under standard conditions and lacked 
further induction under simulated hypoxic conditions.  Introduction of wild-type 
HA-pVHL restored normoxic suppression and CoCl2 induction of HIF-2α.  Type 
2A VHL mutant Y112H cells failed to completely suppress HIF-2α levels, as 
expected due to the predicted disruption of the HIF interaction domain (55).  
Type 2B VHL mutant R167Q cells displayed partial suppression of HIF-2α while 
retaining HIF-2α stabilization in response to CoCl2.  These observations were 
confirmed in multiple independently-derived 786-0 clones (data not shown).  
Type 2B mutant protein participates in a VBC complex containing Cullin2.  
To determine the correspondence between the observed partial retention of HIF-
2α regulation and formation of a competent VBC complex, we analyzed the 
interaction of wild-type and disease-specific mutant HA-pVHL with known 
components of the VBC complex by co-IP and reverse co-IP studies in 
transgenic human 786-0 and murine ES cells.  Based on prevailing models, Type 
2B mutant pVHL proteins, including R167Q, are predicted to disrupt VBC 
complex formation by eliminating Elongin C binding to pVHL (57-59, 260, 261).  
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We have previously observed the inability of R167Q HA-pVHL to bind Elongin C 
in a transgenic murine ES cell system (107).   
 VBC complex formation was assessed by co-IP analysis of proteins 
interacting with HA-pVHL in Vhl-null murine ES cells expressing wild-type pVHL 
(WT), mutants Y112H, R167Q, L188V, and R200W, or no transgene (-/-).  HA-
pVHL pull-down was confirmed in each IP by anti-HA immunoblot (HA, Figure 
2.2A).  Each HA-pVHL-containing complex was then individually tested for 
interaction with known members of the VBC complex through protein-specific co-
IP immunoblot (Figure 2.2A).  As expected based on both previous reports and 
the localization of the respective mutations (51, 107), the R167Q HA-pVHL failed 
to substantially co-immunoprecipitate Elongin C, whereas wild-type HA-pVHL 
and mutant HA-pVHL representing Y112H, L188V, and R200W retained this 
interaction.  Furthermore, wild-type HA-pVHL and mutant HA-pVHL representing 
Y112H, L188V, and R200W demonstrated interaction with complete VBC 
complex detecting the presence of murine Elongin B, Cul2, and Rbx1.  Elongin B, 
Cul2, and Rbx1 also clearly associated with the R167Q HA-pVHL, suggesting 
that the VBC complex is at least partially intact in cells expressing this 
representative Type 2B VHL mutation.   
 In order to discern if the observed remnant VBC complex in R167Q HA-
pVHL-expressing murine ES cells was an artifact of human-mouse interactions, 
we examined the same panel of VHL mutations for VBC complex formation in 
stably-transfected human 786-0 RCC cells.  A second representative Type 2B 
VHL mutation D121G was included in this analysis to determine whether the  
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Figure 2.2. Co-immunoprecipitation of VBC complex proteins with type 2B 
mutant pVHL.  A. Anti-HA immunoprecipitation of HA-pVHL and associated VBC 
complex members in transgenic ES cell clones.  Anti-HA IP products were 
probed for successful pull-down of WT or mutant HA-pVHL and for co-IP of the 
indicated VBC complex members in stably-transfected Vhl-/- murine ES cells.  B. 
and C. Anti-HA immunoprecipitation of HA-pVHL from transgenic 786-0 clones.  
Anti-HA IP products were probed for successful pull-down of WT or mutant HA-
pVHL by anti-pVHL (B) or anti-HA (C) immunoblot and for co-IP of the indicated 
VBC complex members in stably-transfected 786-0 cells. 
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formation of a remnant complex is limited to the specific Type 2B mutant R167Q 
HA-pVHL or is more broadly relevant to Type 2B VHL disease.  Again, pVHL-
associated proteins were co-immunoprecipitated, and pull-down of HA-pVHL was 
confirmed for each IP by anti-VHL (Figure 2.2B) or anti-HA (Figure 2.2C) 
immunoblot, followed by detection of known VBC complex members by protein-
specific co-IP immunoblot (Figures 2.2B and 2.2C).  Both R167Q and D121G 
mutant HA-pVHL failed to demonstrate a strong interaction with Elongin C, 
although robust association was detected for wild-type and the other mutant HA-
pVHL proteins.  The remaining VBC complex members were again associated 
with wild-type and all of the HA-pVHL mutants tested, including the Type 2B 
mutants R167Q and D121G.  This experiment suggests that both of the Type 2B 
mutant HA-pVHL proteins studied may retain at least partial interaction with 
Elongin C and recruit a complex containing the essential human VBC E3 
ubiquitin ligase components CUL2 and ROC1. 
 To confirm the observed interaction between R167Q HA-pVHL and CUL2, 
a myc-tagged CUL2 protein was transiently expressed in stable 786-0 cell lines 
expressing wild-type or RCC-associated mutant HA-pVHL for reverse co-IP 
studies (Figure 2.3).  Cell extracts were subjected to anti-myc-agarose IP, and 
pull-down of myc-CUL2 was confirmed by anti-CUL2 immunoblot.  Anti-HA co-IP 
immunoblot verified the results depicted in Figure 2B-C, displaying myc-CUL2 
interaction with wild-type, Y112H, and R167Q HA-pVHL.   
Type 2B mutant pVHL retains HIF-1α-ubiquitylating activity.  To determine 
if the remnant R167Q HA-pVHL – CUL2 complex retained E3 ubiquitin ligase  
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Figure 2.3. Reverse co-immunoprecipitation confirms CUL2-pVHL protein 
interaction in R167Q mutation.  Anti-myc immunoprecipitation of myc-CUL2 and 
associated HA-pVHL in 786-0 clones.  Stable 786-0 clones expressing vector-
only (ST) or WT or mutant HA-pVHL were transiently transfected with wild-type 
myc-tagged CUL2 and subjected to myc-IP.  Upper panel, IP of Myc-tagged Cul2 
detected by anti-CUL2 immunoblot.  Lower panel, co-IP of WT and mutant HA-
pVHL detected by anti-HA immunoblot. 
 
 
Figure 2.4. pVHL-dependent HIF-1α ubiquitylation in 786-0 cell lines.  Anti-myc 
immunoblot to visualize migration shift of myc-tagged HIF-1α in vitro.  Cell 
extracts from 786-0 clones expressing vector alone or WT or mutant HA-pVHL 
were incubated in the presence or absence of ubiquitylation reaction solution and 
TNT HIF-1α-myc and subjected to anti-myc immunoblot.  A band representing 
unmodified TNT HIF-1α-myc, as depicted in the TNT lane, runs just below the 
ladder marker at 113.9 kDa.  Upward shift of myc-HIF-1α, as seen in complete 
reaction lanes for WT and R167Q, indicates poly-ubiquitylation. The TNT HIF-1α-
myc migration pattern for each complete reaction lane is graphically summarized 
to the right of the immunoblot.   
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activity, wild-type and mutant HA-pVHL were analyzed for competence to 
ubiquitinate HIF-1α using a modified version of the in vitro assay developed by 
Cockman et al. (63).  Exogenous HIF-1α was used as the ubiquitylation target in 
this experiment as the 786-0 parental cell line lacks confounding endogenous 
HIF-1α expression.   The R167Q and a second Type 2B mutation (Q195X)  have 
been shown to retain interaction with HIF-1α (51).  Retention of E3 ligase activity 
by the remnant R167Q mutant pVHL-CUL2 VBC complex, therefore, should 
correspond to preserved HIF-1α ubiquitylation in vitro.   
 In vitro-transcribed (TNT) myc-tagged full-length wild type human HIF-1α 
(HIF-1α-myc) was subjected to a modified in vitro ubiquitylation assay, using anti-
myc immunoblot to visualize ubiquitylation of the HIF-1α-myc substrate (Figure 
2.4, components of each analysis indicated above lane).  The HIF-1α-myc 
protein migration for each cell line is summarized by a shaded line to the right of 
the immunoblot. TNT HIF-1α-myc substrate in the absence of reaction solution or 
cell extract served as a negative control for the unmodified electrophoretic 
mobility of the HIF-1α-myc protein. For each cell line in our assay, further 
controls were provided by excluding cell extract (first reaction) or TNT HIF-1α-
myc substrate (second reaction).  The third reaction for each cell line contained 
all three necessary components for the ubiquitylation reaction.  An upward shift in 
HIF1α-myc mobility, as exemplified by the wild-type (WT) complete reaction, 
indicates HIF-1α-myc poly-ubiquitylation.  The HIF-1α-myc protein was shifted 
only slightly upwards in the reaction utilizing extract from control vector-only 786-
0 cells, demonstrating the basal pVHL-independent HIF-1α ubiquitylation present 
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in this system.  Type 2A Y112H mutant HA-pVHL failed to promote HIF-1α-myc 
mobility shift beyond basal levels, confirming previous work by Cockman et al. 
(63).  Notably, Type 2B R167Q mutant HA-pVHL promoted HIF-1α-myc mobility 
shift similar to WT HA-pVHL, demonstrating that the remnant R167Q HA-pVHL – 
Cullin-2 complex retains E3 ligase activity towards HIF-1α in vitro.   
Discussion 
 In addition to the strong association of sporadic ccRCC with biallelic VHL 
inactivation and of VHL disease-associated ccRCC with subtype-specific 
germline VHL mutations, evidence from xenograft models of tumor growth 
strongly supports the requirement for pVHL-mediated HIF regulation in 
suppression of renal tumorigenesis.  However, several lines of evidence suggest 
that dose-dependent effects on basal HIF levels influence VHL-associated tumor 
development and behavior.  Our prior investigation in eupoloid primary ES cell 
lines, utilized as a strategy to avoid interference from transforming cancer cell 
events, demonstrated a bias toward HIF-2α dysregulation for VHL Type 2B 
mutation, and a graduated degree of HIF dysregulation across the disease 
subtypes (107).  In vitro studies of RCC-predisposing Type 2A and Type 2B VHL 
missense mutations have revealed a correlation between the degree of mutant 
pVHL-mediated HIF-α dysregulation and risk of ccRCC (259).  In a recent study 
performed in both 786-0 and a second RCC-derived cell line, RCC4, 
representative Type 2A and Type 2B VHL mutations demonstrated intermediate 
levels of HIF stabilization (257).  Taken together, these results suggest that Type 
2A and Type 2B mutant pVHL proteins retain an intermediate degree of HIF 
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regulation, rather than an “all-or-none” pattern of regulation, likely contributing to 
the distinct phenotypes observed in these VHL disease subtypes.  
 In this study, we observed intermediate HIF regulatory activity by Type 2A 
Y112H and Type 2B R167Q mutant HA-pVHL, which could underlie the distinct 
genotype-phenotype correlations and may provide insight into the biology of 
sporadic RCC as well.  In previous reports of VBC complex formation, the ability 
of disease-specific mutant pVHL to bind Elongin C was used as a proxy for ability 
to recruit the remainder of the VBC complex.  The absence of 2B mutant HA-
pVHL interaction with Elongin C in co-IP studies led to conclusions that α-domain 
mutations in pVHL abolish VBC complex formation (57-59, 260, 261).  We report 
here, however, that both R167Q and D121G Type 2B mutant HA-pVHL 
participate in a complex with CUL2, ROC1, and Elongin B, as well as potentially 
with Elongin C either transiently or with greatly reduced abundance.   
 The co-immunoprecipitation of VBC complex members with R167Q and 
D121G mutant HA-pVHL could be due to reduced or transient formation of a 
wild-type VBC complex and/or formation of an alternate pVHL-Cullin-2 complex 
with ubiquitin ligase activity.  The low abundance of Elongins C and B in 
association with both representative Type 2B mutant pVHL proteins may 
represent a limited quantity of stable complete VBC complex.  Existing crystal 
structures depict the pVHL α-domain interacting with the VBC complex only 
through Elongin C (55). However, the relatively abundant CUL2 and ROC1 in the 
mutant 2B VBC complex could point to a direct interaction between mutant HA-
pVHL and CUL2 or the replacement of Elongins C and B with alternate adaptors 
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linking the mutant HA-pVHL to CUL2 – ROC1.  Silver stain and proteomic 
analysis of our Type 2B mutant HA-pVHL immunoprecipitates failed to detect 
additional bands that could function as replacement adaptors in an alternate HA-
pVHL – CUL2 complex (data not shown). 
 The Type 2B mutation R167Q has been shown to permit interaction 
between pVHL and HIF-α (51).  Therefore, if able to recruit an active complete or 
alternate VBC complex, Type 2B pVHL should be able to direct HIF-α 
ubiquitylation.  Indeed, we observed that R167Q mutant HA-pVHL existed in 
complex with CUL 2 and ROC1 and mediated wild-type levels of HIF-1α poly-
ubiquitylation in vitro.  Though the presence of ROC1 has been shown to 
stabilize the VBC complex (255), our results cannot discern whether endogenous 
levels of Type 2B mutant pVHL expression support formation of a stable or 
transient complex with CUL2.  R167Q mutant pVHL has been shown to be 
relatively unstable in vitro (259), and subtype-specific clinical manifestations of 
VHL disease may derive from a combination of mutant pVHL stability and the 
stability and activity of the mutant VBC complex.  
 In summary, we have demonstrated that disease-associated mutant pVHL 
proteins retain endogenous HIF-2α regulation.  Two representative Type 2B 
mutant pVHL proteins partially preserved interaction with VBC complex members 
despite reduced binding to Elongin C, and the Type 2B mutant R167Q pVHL 
retained wild-type levels of ubiquitin ligase activity towards its target HIF-1α in 
vitro.  Taken together, our results show that at least a subset of Type 2B VHL 
missense mutations result in a partial or unstable but active VBC complex which 
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retains the ability to regulate HIF-α levels. Furthermore, our results support 
observations that VHL missense mutations generally confer lower levels of HIF-α 
stabilization than null or truncating Type 1 VHL mutations (107, 257) and provide 
mechanistic insight into this retained ubiquitin ligase activity.   
Materials and methods 
 Cell Lines.  Vhl-null embryonic stem (ES) cells or VHL-deficient 786-0 
RCC cells were transfected with vectors specifying human wild-type VHL or 
representative VHL mutants Y112H (Type 2A), R167Q (Type 2B), L188V (Type 
2C), or R200W (Chuvash polycythemia) using vectors and techniques as 
previously described (107).  786-0 cells expressing the VHL mutant D121G 
(Type 2B), generated as previously described (262), were generously provided 
by Dr. William Kim, Chapel Hill, NC.  Vhl-null murine ES cells and transfected 
derivatives were maintained in culture media comprised of Dulbecco’s Modified 
Eagle Medium (DMEM, various manufacturers), supplemented with 10% ES cell-
certified fetal bovine serum (Invitrogen, Carlsbad, CA), non-essential amino 
acids, L-glutamine, 2-mercaptoethanol, and leukemia inhibitory factor, and were 
grown on gelatin-coated plates in the absence of feeder cells.  Renal cell 
carcinoma 786-0 cells were acquired from the American Type Culture Collection 
(Manassas, VA).  786-0 cells and transfected derivatives were maintained in 
DMEM, supplemented with 10% FBS, non-essential amino acids, L-glutamine, 
and 2-mercaptoethanol.  All cultures were maintained at 37ºC in 5% CO2.  For 
hypoxia mimetic experiments, cells in log-phase growth were placed in media 
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supplemented with 100mM cobalt chloride (Sigma, St. Louis, MO) or fresh 
unsupplemented media.   
 Immunoblot analysis.  Cells were lysed in Mammalian Protein Extraction 
Reagent (M-PER; Pierce Biotechnology, Rockford, IL) supplemented with 
Complete Mini Protease Inhibitor Cocktail (Roche, Basel, Switzerland).  The 
Bradford Quantification Method (Amresco, Solon, OH) was used to determine 
protein concentration.  Cell lysates were resolved by SDS-PAGE and 
subsequently transferred to Hybond ECL nitrocellulose membrane (GE 
Healthcare, United Kingdom).  Immediately following transfer, membranes were 
stained with Ponceau S to confirm even transfer, blocked in 5% nonfat dry milk 
diluted in phosphate-buffered saline containing 0.1% Tween-20 (PBS-T), and 
then probed with the following primary antibodies:  rabbit polyclonal anti-HA tag 
(Abcam, Cambridge, MA: ab9110, 1:1000), mouse monoclonal anti-pVHL 
(Abcam, ab11189, 1:2000), rabbit polyclonal anti-cullin-2 (Abcam: ab1870, 
1:1000), rabbit polyclonal anti-ROC1 (Abcam: ab2977, 1:500), goat polyclonal 
anti-Elongin C (Santa Cruz, Santa Cruz, CA: sc-1559, 1:200), rabbit polyclonal 
anti-Elongin B (Santa Cruz: sc-11447, 1:200), mouse monoclonal anti-Myc tag 
(Cell Signaling, Danvers, MA: 9B11, 1:1000), mouse monoclonal anti-HIF-2α 
(GeneTex, San Antonio, TX: GTX30123, 1:1000), and rabbit polyclonal anti-Ku80 
(GeneTex: GTX70485, 1:2000).  Secondary antibodies used were anti-mouse, 
anti-rabbit, and anti-goat IgG conjugated to horseradish peroxidase (various 
manufacturers) and detected with the ECL Plus Western Blotting System (GE 
Healthcare) using exposure to BlueLite autoradiography film (ISC BioExpress, 
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Kaysville, UT) and processing via a Kodak RP X-OMAT Processor (Rochester, 
NY).   
 Immunoprecipitation analysis.  M-PER cell lysates were subjected to 
immunoprecipitation (IP) using either the Profound Mammalian HA Tag IP/Co IP 
Kit or the Profound Mammalian Myc Tag IP/Co IP Kit, as per manufacturer’s 
specifications (Pierce Biotechnology).  For the reverse co-IP analysis, stably-
transfected 786-0 cell lines were transiently transfected with a plasmid encoding 
myc-tagged cullin-2, a generous gift from Dr. Y. Xiong, Chapel Hill, NC, using 
Solution V of the Amaxa Tranfection System (Amaxa, Gaithersberg, MD).  
Twenty hours post-transfection, transfected cells were incubated in media 
supplemented with 5 μM MG-132 (Calbiochem, Gibbstown, NJ) proteasome 
inhibitor or fresh unsupplemented media for four hours, followed by protein 
extraction with M-PER and IP analysis as above.   
 In vitro HIF-1α ubiquitylation assay.  An in vitro ubiquitylation assay was 
adapted from the protocol developed by Cockman et al. (63).  786-0 cell lines 
incubated for four hours in 5μM MG-132 were washed and collected in PBS.  The 
cells were then washed twice in Ub Extraction Buffer (20 mM Tris, pH 7.5, 5 mM 
Kcl, 1.5 mM MgCl2, 1 mM DTT) and disrupted using a dounce homogenizer.  The 
cell lysates were centrifuged at 10,000xg for 10 minutes at 4°C.  Each reaction 
was set up in a total volume of 40 μL, containing 23 μL cell extract, 5 μL HIF1α-
myc substrate, and 12 μL reaction solution.  The “reaction solution” was 
composed of ATP Regenerating System (20mM Tris, pH 7.5, 10mM ATP (GE 
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Healthcare)), 10mM magnesium acetate (Promega Corporation, Madison, WI), 
300 mM creatine phosphate, 0.5 mg/mL creatine phosphokinase (MP 
Biomedicals, LLC, Irvine, California), 20 μg ubiquitin, and 150 uM ubiquitin 
aldehyde (Biomol International, Plymouth Meeting, PA). When reactions 
excluded a specific component, nuclease-free dH2O was substituted to maintain 
the total reaction volume.  Reactions were incubated at 30°C for 270 minutes and 
then subjected to immunoblot analysis.  HIF1α-myc substrate was produced 
through TNT® coupled Wheat Germ Extract Systems (Promega, Madison, WI) 
from a plasmid encoding full-length functional human HIF1α-myc protein, a 
generous gift from Dr. M. C. Simon, Philadelphia, PA.   
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CHAPTER THREE 
VHL Type 2B gene models HIF-2α dysregulation in vitro and in vivo 
Modified from Lee CM et al. 2009 (263). 
Abstract 
 Von Hippel-Lindau (VHL) disease is caused by germline mutations in the 
VHL tumor suppressor gene, with Type 2B missense VHL mutations 
predisposing to renal cell carcinoma, hemangioblastoma, and 
pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in 
hypoxia inducible factor (HIF)-α regulation.  Murine embryonic stem (ES) cells in 
which the endogenous wild-type Vhl gene was replaced with the representative 
Type 2B VHL hotspot mutation R167Q (Vhl2B/2B) displayed preserved physiologic 
regulation of both HIF factors with slightly more normoxic dysregulation of HIF-
2α.  Differentiated Vhl2B/2B-derived teratomas over-expressed the joint HIF targets 
Vegf and EglN3 but not the HIF-1α-specific target Pfk1 and displayed a growth 
advantage over Vhl-/--derived teratomas, suggestive of a tight connection 
between perturbations in the degree and ratio of HIF-1α and HIF-2α stabilization 
and cell growth.  Vhl2B/2B mice displayed mid-gestational embryonic lethality, 
while adult Vhl2B/+ mice exhibited susceptibility to carcinogen-promoted renal 
neoplasia compared with wild-type littermates at twelve months.  Our 
experiments support a model in which the representative Type 2B R167Q mutant 
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pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-
specific effects on cell growth, development, and tumor predisposition. 
Introduction 
 Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited 
cancer susceptibility syndrome resulting from germline mutation of the VHL 
tumor suppressor gene which affects 1 in 36,000 live births in the US (27, 28).  
Specific classes of VHL mutations predispose to different spectrums of morbidity- 
and mortality-causing clinical phenotypes of VHL disease: retinal and central 
nervous system (CNS) hemangioblastoma, pheochromocytoma/paraganglioma, 
and renal cell carcinoma with clear cell histology (ccRCC) (48, 49).  Type 1 VHL 
mutations predispose to ccRCC and hemangioblastoma (50).  Type 2 missense 
VHL mutations predispose to pheochromocytoma, either alone (Type 2C) or in 
combination with hemangioblastoma and a high (Type 2B) or low (Type 2A) risk 
of ccRCC (51).  Finally, individuals with homozygosity for the germline R200W 
VHL mutation develop Chuvash Polycythemia (CP), a rare benign congenital 
erythrocytosis with no associated cancer risk (52, 53). 
 The VHL gene encodes a 30 kDa protein, pVHL (21, 264). Wild-type pVHL 
has been reported to play roles in diverse biological processes including acting 
as the recognition domain for an E3 ubiquitin ligase complex (61, 62) composed 
of Elongins B and C (56, 57), cullin-2 (58), ROC1 (Rbx1) (60), and an E2 
conjugating enzyme (61, 256).  pVHL E3 ligase activity targets hypoxia inducible 
factor (HIF)-α subunits (63-66), a family of transcription factor subunits including 
HIF-1α and HIF-2α. 
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 HIF-1α and HIF-2α coordinate cellular and whole-organism responses to 
hypoxia and are controlled at the level of stability and activity by oxygen-
dependent hydroxylation.  In normoxic conditions, a family of prolyl hydroxylases 
(74, 126, 127, 129) mediates the hydroxylation of HIF-α prolyl residues (71, 72, 
128, 130), targeting HIF-α to pVHL for degradation (73, 75).  In hypoxic 
conditions, the prolyl hydroxylases are inactive (127, 130, 265), resulting in 
stabilized, transcriptionally active HIF-α.  Stabilized HIF-α heterodimerizes with 
ARNT/HIF-1β (76) to activate the transcription of target genes (77, 78).    HIF-1α 
and HIF-2α target gene sets overlap in a highly context-dependent manner (79), 
but HIF-1α uniquely activates glycolytic enzymes (83).   
 Several lines of evidence implicate the VHL/HIF axis in the initiation of 
renal tumorigenesis.  First, biallelic inactivation of VHL and over-expression of 
HIF targets is observed in both VHL disease-associated renal lesions and also 
70-90% of sporadic ccRCC tumors (252, 266-268).  Second, over-expression of 
HIF targets accounts for many histological and clinical features of ccRCC tumors, 
including their highly vascular natures and paraneoplastic erythrocytosis (269).  
Third, Vhl loss in primary cells directly results in upregulation of both HIF-1α and 
HIF-2α and recapitulates many features of RCC (106).  Finally, emerging 
evidence points to the degree of HIF dysregulation impacting renal 
tumorigenesis.  In vitro studies of cDNA expressed Type 2A and Type 2B mutant 
pVHL models revealed graded dysregulation of HIF-1α and HIF-2α (51, 63), 
correlating with the degree of risk for ccRCC (Type 1≥ Type 2B > Type 2A) (257, 
259).  Additionally, while Type 2B mutations are predicted to disrupt 
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pVHL:Elongin C interactions, preservation of HIF ubiquitylation activity has been 
observed, which would provide a permissive environment for HIF regulation 
(Hacker et al, 2008).  The profile of HIF dysregulation may also have 
ramifications for tumor predisposition, as selective HIF-2α stabilization has been 
observed in murine embryonic stem (ES) cells transgenic for a Type 2B mutant 
VHL gene (107).  These systems in addition to demonstrating mutation specificity 
are sensitive to pVHL levels. 
 Existing mouse models of VHL disease utilize null (110) or conditional null 
(111, 116) Vhl alleles, display homozygous embryonic lethality, and show a high 
penetrance of hepatic angiomas, uncommon in the human disease.  A Vhl gene 
replacement model of Chuvash Polycythemia, however, was viable and 
conferred erythrocytosis in a milieu of very mild HIF-2α stabilization (112). To 
examine the activities of mutant pVHL relevant to human cancer, particularly with 
respect to missense mutation-specific effects on HIF regulation, we undertook a 
gene replacement approach to study Type 2B VHL disease in a mouse model.  
This model provides the first opportunity to examine the effect of a VHL disease-
causing missense mutations in its pre-malignant context and under endogenous 
transcriptional, translational, and post-translational regulation.  Murine ES cells 
homozygous for a representative mutant 2B Vhl allele displayed mild HIF-2α 
stabilization but functionally preserved HIF-1α suppression.  In vivo, while 
homozygosity for the mutant 2B Vhl allele conferred mid-gestational embryonic 
lethality, heterozygous Vhl2B/+ mice were viable and susceptible to carcinogen-
promoted renal adenocarcinoma.  Our genetic knock-in mouse model thus 
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provides a species-congruent cellular system and in vivo model in which to 
further examine the contributions of Type 2B VHL missense mutation to VHL 
disease-associated cancers. 
Results 
 Generation and characterization of Type 2B Vhl ES cell lines.  The 
Arginine 167 ? Glutamine (R167Q) missense mutation is a hotspot in the human 
VHL gene with a tight genotype-phenotype correlation to Type 2B disease (27, 
49).  Localized to the pVHL α helical domain (Figure 3.1A), R167 is predicted to 
stabilize the α/β domain interface and interaction with Elongin C (55, 261).  In the 
murine Vhl allele, this mutation corresponds to a guanine to alanine transition at 
position 518 (G518A).     
 To study the effect of 2B mutant pVhl on regulation of HIF-α and HIF 
targets, we targeted the endogenous murine Vhl locus with an R167Q mutant Vhl 
construct (Figure 3.1B) to generate Vhl2B/+ and Vhl2B/2B ES cell lines.  The 
targeting construct introduced a HindIII site, enabling verification of 
recombination by Southern analysis (Figure 3.1C), and the G518A mutation 
introduced a novel HpyIV restriction site for restriction-based PCR genotyping 
(Figure 3.1D).  Quantitative RT-PCR analysis in Vhl2B/2B ES cells confirmed that 
2B mutant Vhl was transcribed at wild-type levels (Figure 3.2A).  Vhl2B/+ cells 
expressed wild-type levels of pVhl, but Vhl2B/2B cells expressed greatly reduced 
levels of the 2B mutant pVhl (Figure 3.2B).  A similar reduction in detectable 2B  
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Figure 3.1.  Type 2B Vhl mutation knock-in strategy and genotyping.  A.  
Human:Mouse pVHL protein alignment.  The R167Q pVHL substitution 
representing human Type 2B VHL disease is embedded in a highly homologous 
region.  B.  Type 2B mutant murine Vhl containing the G518A (R167Q) 
representative missense mutation (star) was prepared with site-directed 
mutagenesis and then cloned into the targeting vector as shown.  Following 
electroporation of the targeting vector into J1 ES cells, neomycin and gancyclovir  
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mutant pVhl was also observed by immunoblot with an antibody raised against 
an alternate epitope suggesting that reduced detection of 2B mutant pVhl was 
not due to epitope-masking alone.  Rescue with MG-132 treatment was not 
observed, consistent with the reduced protein expression and incomplete MG-
132 rescue observed in the Chuvash Polycythemia Vhl gene replacement model 
(112). 
 Analysis of HIF and HIF target expression in Type 2B Vhl ES cells.  The 
R167Q human pVHL mutation is predicted to destabilize the pVhl protein (259) 
and to disrupt pVhl recruitment of Elongin C (55), resulting in HIF factor 
dysregulation.  ES cells in the presence or absence of the chemical hypoxia 
mimetic cobalt chloride (CoCl2) were examined for HIF-1α (Figure 3.2C) and HIF-
2α (Figure 3.2D) protein levels by immunoblot.  Wild-type and Vhl2B/+ ES cells 
displayed low basal levels of HIF-1α and HIF-2α and responded to CoCl2 
exposure with induction of both factors.  Vhl-/- ES cells displayed maximal 
stabilization of both HIF-1α and HIF-2α without further induction.  In contrast, 
Vhl2B/2B ES cells retained physiologic induction of both HIF-α factors with CoCl2.   
 
Figure 3.1. continued.  resistance was used to select clones with homologous 
recombination at the endogenous murine locus (Neo-in).  Cre recombinase 
exposure in vitro or in vivo resulted in excision of the floxed NeoR cassette (Neo-
out).  C. Southern blot genotyping distinguished between wild-type and targeted 
Vhl alleles based on the introduction of new HindIII restriction sites.  HindIII-
digested murine Vhl was detected with a probe recognizing the Vhl 3’ 
untranslated region (UTR, bar).  D. Restriction PCR was used as an alternative 
genotyping strategy.  Primers (arrows) flanking the targeted mutation generated 
a 300-bp PCR product.  The novel restriction site introduced by the G518A 
mutation rendered the targeted Vhl-origin PCR product susceptible to HpyIV 
digestion. 
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While normoxic HIF-1α levels in Vhl2B/2B cells were similar to wild-type cells in 
independently-derived clones (Figure 3.2C), normoxic HIF-2α levels tended to be 
modestly elevated (Figure 3.2D).  Qualitative comparisons were confirmed by 
densitometry analysis (Figure 3.3).   
 HIF-2α is transcriptionally inactive in ES cells (270).  To determine 
whether Vhl2B/2B ES cells activate transcription of HIF target genes, we performed 
quantitative (q) RT-PCR for four known HIF target mRNAs (Figure 3.2E): the joint 
HIF-1α and HIF-2α targets vascular endothelial growth factor (Vegf), glucose 
transporter 1 (Glut1), and prolyl hydroxylase three (EglN3) and the HIF-1α-
specific glycolytic enzyme phosphofructokinase (Pfk1).  Vhl-/- ES cells displayed 
transcription of all four HIF target mRNAs relative to wild-type J1 cells (p<0.05): 
Vegf (4.26-fold), Glut1 (2.66-fold), EglN3 (11.80-fold), and Pfk1 (2.32-fold).    Two 
independently-derived Vhl2B/2B clones, in contrast, failed to significantly over-
transcribe any of the four HIF targets, consistent with the observation that 
Vhl2B/2B ES cells exhibit wild-type HIF-1α expression.  Mirroring the qRT-PCR 
results, Vhl-/- ES cells secreted robust levels of Vegf protein (4.4-fold) compared 
to wild-type (p<0.01), while Vhl2B/2B ES cells did not secrete measurable Vegf 
(Figure 3.2F). 
 Type 2B Vhl promotes teratoma growth and vascularization.  To observe 
the functional effects of Type 2B Vhl mutation, we differentiated our panel of ES 
cells in a teratoma assay.  As expected from previous studies (107), Vhl-/--derived 
teratomas displayed a growth disadvantage.  In contrast, the presence of one or 
two Type 2B Vhl alleles conferred a persistent growth advantage, such that
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Figure 3.2.  The Type 2B Vhl missense mutation results in a post-transcriptional 
reduction in mutant pVHL levels and slight normoxic HIF dysregulation but 
normal normoxic suppression of HIF target gene transcription in ES cells.  A. 
Quantitative RT-PCR analysis for Vhl cDNA levels in ES cells relative to 
expression of the wild-type allele.  Quantitation was normalized to an internal 
18S ribosomal RNA standard.  Error bars indicate standard error of the mean 
(SEM).  B.-D. Immunoblots for pVhl (B.), HIF-1α (C.), and HIF-2α (D.) expression 
in ES cells treated with or without the hypoxia mimetic CoCl2 (Co) for four hours.  
E.  Quantitative RT-PCR for normoxic transcriptional activation of HIF targets 
Vegf, Glut1, EglN3, and Pfk1 in ES cells relative to J1.  Cycle thresholds were 
corrected with 18S ribosomal RNA.  Error bars indicate SEM.  *p<0.05 in paired 
comparison to J1.  ELISA for secreted Vegf protein in ES cells relative to J1.  
*p<0.01 in paired comparison to J1. 
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Vhl2B/2B-derived teratomas grew faster than Vhl2B/+-derived teratomas, which in 
turn grew faster than wild-type teratomas (Figure 3.4A).  At harvest, J1, Vhl-/-, 
and Vhl2B/+ teratomas were well-encapsulated, while Vhl2B/2B teratomas adhered 
to the overlying skin (not shown).  Vhl2B/2B teratomas (Figure 3.4B, left) were also 
grossly hemorrhagic compared to Vhl2B/+ (Figure 3. 4B, right) teratomas.  
Histologically, Vhl-/- teratomas were characterized by hemangioma (*) formation 
(Figure 3.4E), which was markedly enhanced in Vhl2B/2B teratomas (Figure 3.4F).   
 To determine whether Type 2B mutant pVhl preserves HIF regulation in 
vivo, teratomas were analyzed for HIF-1α and HIF-2α protein expression by 
immunoblot, confirming low levels of both HIF factors (Figure 3.5).  To evaluate 
the effect on target gene expression, we performed quantitative RT-PCR for the 
panel of HIF target genes described above in three independent sets of 
teratomas.  In one representative set (Figure 3.4G), the Vhl-/- teratoma displayed 
highly significant (p<0.001) over-expression of three of the four HIF targets 
relative to the J1 teratoma: Vegf (1.99-fold), EglN3 (3.15-fold), and Pfk1 (2.12-
fold).  In contrast to ES cells, the Vhl2B/2B-derived teratoma exhibited significant 
over-expression of both EglN3 (1.46-fold, p<0.05) and Vegf (1.87-fold, p<0.001) 
but failed to over-express the HIF-1α-specific target Pfk1.  Glut1 expression was 
not elevated for either Vhl mutant in this differentiated system. 
 Because Vegf expression alone was unlikely to account for the dramatic 
difference in vascularity between Vhl-/- and Vhl2B/2B teratomas, we performed a 
screen for candidate genes contributing to the vascular phenotype.  The same 
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Figure 3.3.  Densitometry analysis for ES cell HIF-1α and HIF-2α immunoblots.  
Experimental band intensity for each sample was determined relative to the 
corresponding loading control band using the ImageJ gel analysis tool. Co, 
treatment with Cobalt Chloride.    
 
Figure 3.4 (next page). Homozygous Type 2B Vhl teratomas display growth 
advantage, enhanced hemangioma formation, and transcriptional dysregulation 
of HIF target genes.  A. Growth curve for ES cell-derived teratomas (n=6 per 
genotype).    Error bars indicate SEM.  B. Gross appearance of representative 
Vhl2B/2B (left) and Vhl2B/+ teratomas.  C.-F. Histological analysis of representative 
J1 (C.), Vhl-/- (D.), Vhl2B/+ (E.), and Vhl2B/2B (F.) teratoma morphology by H&E at 
20X magnification.  Note enhanced hemangioma (*) formation and hemorrhage 
in Vhl2B/2B relative to Vhl-/- teratoma.  Scale bars indicate 100µm.  G. Quantitative 
RT-PCR for transcriptional activation of HIF targets Vegf, Glut1, EglN3, and Pfk1 
in representative set of teratomas relative to J1.  Cycle thresholds were corrected 
with 18S ribosomal RNA.  Error bars indicate standard deviation.  *p<0.05.  
**p<0.001.  
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Figure 3.5.  Homozygous Type 2B teratomas display sub-maximal HIF 
stabilization compared to null.  Immunoblots for HIF-1α (A), and HIF-2α (B), and 
eEF2 and actin (loading controls, respectively) on extracts prepared from fresh 
teratoma tissue harvested at six weeks post-injection.     
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three independent sets of teratomas described above were assayed for 
expression of 84 angiogenesis-related genes using the commercial qRT-PCR 
RT2 Profiler system.  Genes selected for further assessment were significantly or 
near-significantly (p<0.06) over-expressed (>2.0-fold) or under-expressed (<0.3-
fold) in one Vhl-/- and/or Vhl2B/2B teratoma relative to the average expression of 
three independent J1 teratomas.   
 Four novel angiogenesis-related candidate genes, in addition to Vegfa, 
were uncovered in the candidate screen and validated by qRT-PCR with 
independent primers : vascular endothelial (VE)-cadherin (Cdh5), the TgfβR 
endothelial co-receptor endoglin (Eng), Vegf receptor 2 (Kdr), and the Vegfr2 co-
receptor neuropilin-1 (Nrp1).  All four are considered direct HIF targets (271-274).  
While both the Vhl-/- and Vhl2B/2B teratomas significantly over-expressed Cdh5, 
Eng, and Kdr relative to the J1 teratoma, the Vhl2B/2B teratoma additionally 
significantly (p<0.001) over-expressed Nrp1 relative to both J1 and Vhl-/- (Figure 
3.6A).    
 To further explore the differences in vascular proclivity between Vhl-/- and 
Vhl2B/2B teratomas, we examined the ability of embryoid bodies derived from ES 
cells of each genotype to differentiate into primitive vascular structures in vitro.  
As visualized by PECAM immunofluorescence, J1-derived embyroid bodies 
developed a vascular plexus consisting of long, well-formed primitive vessels 
with branching at regular intervals (Figure 3.6B).  Vhl-/--derived embryoid bodies  
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Figure 3.6. Exploration of hyper-angiogenic phenotype of homozygous Type 2B 
Vhl teratomas.  A. Quantitative RT-PCR for transcriptional activation of 
angiogenesis-related genes Cdh5, Eng, Kdr, Nrp1, and Vegfc in a representative 
set of teratomas relative to J1.  Cycle thresholds were corrected with 18S 
ribosomal RNA.  Error bars indicate standard deviation.   *p<0.05.  **p<0.001. B.-
D. PECAM immunofluorescent visualization of vascular structures generated 
from in vitro differentiation of embryoid bodies derived from J1 (B.), Vhl-/- (C.), 
and Vhl2B/2B (D.) ES cells.  
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differentiated into large, diffuse clumps of PECAM-positive cells but failed to 
sprout primary vessels (Figure 3.6C).  Finally, Vhl2B/2B-derived embyroid bodies 
differentiated into a disorganized vascular plexus characterized by relatively short 
primitive vessels with haphazard, excessive sprouting and a background of 
unincorporated PECAM-positive cells (Figure 3.6D).  Altogether, these results 
suggest that the Vhl2B/2B genotype engenders conditions more permissive for 
angiogenesis and cell growth than the Vhl-/- genotype.   
 Homozygosity for Type 2B Vhl confers embryonic lethality.  To examine 
2B mutant pVhl function in murine development in vivo, we derived Vhl2B/+ knock-
in mice from our targeted murine ES cells.  Inter-heterozygous matings resulted 
in a 2:1 ratio of Vhl2B/+ to wild-type pups and a complete absence of Vhl2B/2B pups 
(Table 3.1).  To pinpoint the window of Vhl2B/2B intrauterine demise, we 
genotyped embryos resulting from timed matings at embryonic day (E) 9.5 and 
E10.5.  While Vhl2B/2B embryos were present at near-expected levels at E9.5, 
only one Vhl2B/2B embryo (3%) survived at E10.5.  Because reliance switches 
from yolk sac to placenta around E9.5 (275), Vhl2B/2B embryonic lethality 
observed at E9.5-E10.5 implicates placental failure.   
Table 3.1. Vhl genotype analysis of inter-heterozygous matings at birth and 
embryonic time points.   
 
Vhl E9.5 E10.5 Birth 
+/+ 14 (32%) 13 (45%) 60 (36%) 
2B/+ 20 (49%) 15 (52%) 107 (64%) 
2B/2B 8 (19%) 1 (3%) 0 (0%) 
Total 42 29 167 
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 Vhl-/- embryos display embryonic lethality at E9.5-E12.5 due to an 
embryonic-origin defect in placental labyrinth vascularization.  While the 
presumptive Vhl-/- labyrinth is normal in histological appearance at E9.5, Vhl-/- 
allantoic vessels fail to invade the chorionic plate, preventing induction of 
chorionic plate trophoblast cell differentiation into syncitiotrophoblast cells and 
later manifesting as an absence of fetal blood spaces in the labyrinth at E10.5 
(110).  To visualize whether the 2B mutant Vhl allele acts similarly to the null 
allele in the placenta, we compared wild-type (not shown), Vhl2B/+, and Vhl2B/2B 
placentas by H&E for morphology and IHC for pVhl and the HIF target Vegfa.  By 
H&E, representative E9.5 Vhl2B/+ (Figure 3.7A) and Vhl2B/2B (Figure 3.7D) 
placentas displayed comparable chorionic villous fold formation and maternal red 
blood cell content in the spongiotrophoblast layer, but allantoic vessels, 
demarcated by the presence of nucleated fetal red blood cells (*), invaded the 
chorionic villi to a lesser extent in the Vhl2B/2B placenta.  Despite the reduced 
Type 2B pVhl levels observed by immunoblot in Vhl2B/2B ES cells, 
spongiotrophoblast and giant cell pVhl expression was comparable between 
representative Vhl2B/2B (Figure 3.7E) and Vhl2B/+ (Figure 3.7B) placentas by IHC.  
Finally, consistent with findings in Vhl-/- placentas at E10.5 (110), Vhl2B/2B 
placenta (Figure 3.7F) displayed absent or greatly reduced spongiotrophoblast 
and giant cell Vegf expression relative to Vhl2B/+ (Figure 3.7C) by IHC.  While 
perhaps counter-intuitive, evidence supports decreased Vegf expression as a 
marker of placental failure rather than an indicator of HIF dysregulation in the 
murine placenta (276). 
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Figure 3.7.    Homozygous Type 2B Vhl placentas display subtle vascular 
defects consistent with a Vhl-null phenotype, and corresponding embryos display 
HIF target dysregulation despite normal morphology.  A.-F.  Histological analysis 
of Vhl2B/+ (A.-C.) and Vhl2B/2B (D.-F.) murine placentas, with H&E stain for 
morphology (A., C.) and immunohistochemistry for pVhl (B., E.) and for the HIF 
target Vegfa (C., F.) at 10X magnification.  Arcs demarcate the maternal decidua 
(above) and placental (below) tissues.  Note the lack of nucleated fetal RBCs (*) 
in the chorionic villi in Vhl2B/2B (D.) versus Vhl2B/+ (A.) placentas. G. Quantitative 
RT-PCR for transcriptional activation of HIF targets Vegf, Glut1, EglN3, and Pfk1 
in E9.5 Vhl2B/2B embryos relative to representative Vhl2B/+ littermate.  Cycle 
thresholds were corrected with 18S ribosomal RNA.  Error bars indicate SEM.  
*p<0.05.  **p<0.001. 
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 Because E9.5 embryos were the only Vhl2B/2B animal tissues available for 
molecular study, we used these tissues to analyze the competence of Type 2B 
pVhl to regulate HIF target genes in vivo.  Though Vhl2B/2B embryos are grossly 
and histologically normal at E9.5, we hypothesized that they might still 
demonstrate subtle HIF target gene dysregulation. Quantitative RT-PCR on three 
Vhl2B/2B E9.5 embryos showed significant (p<0.05) over-expression of the four 
HIF target genes studied relative to a Vhl2B/+ E9.5 embryo, paralleling the effect 
of Vhl mutation on HIF-regulated signaling observed in the differentiated 
teratoma model system (Figure 5G): Vegf (average 1.54–fold), Glut1 (average 
2.60–fold), EglN3 (average 3.53–fold), and Pfk1 (average 1.88–fold).  In notable 
contrast to ES cells and teratomas and in keeping with the reported highly tissue- 
and context-specific transcriptional effects of HIF stabilization, homozygosity for 
the 2B Vhl allele produced sufficient HIF-1α dysregulation to permit over-
expression of the HIF-1α-specific target Pfk1 in the E9.5 embryo, with potential 
contribution by physiologic embryonic hypoxia.   
 Heterozygous Type 2B Vhl mice develop renal cysts.  As Type 2B VHL 
disease predisposes to pheochromocytoma, hemangioblastoma, and ccRCC in 
humans, Vhl2B/+ mice (n=105) were aged to three, six, nine, twelve, and eighteen 
months and observed for tumor susceptibility. Representative H&E images of 
Vhl2B/+ tissues at twelve months are presented in Figure 3.8 (A-C).  Similar to 
prior models, Vhl2B/+ mice displayed frequent enlarged vessels (angiectasis) in 
the kidney and adrenal gland (Figure 3.8B, *) (110, 111, 116) and renal cortical 
microcysts (3%, Figure 3.8A, Cy) (111).  Renal cortical cysts were not observed 
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Figure 3.8.  Adult Type 2B Vhl heterozygous mice develop mild vascular lesions 
and rare renal cortical microcysts, while transplacental ENU mutagenesis reveals 
renal tumor predisposition.  A. – D. Histological analysis of representative adult 
Type Vhl2B/+ mouse tissues, including kidney (A.), adrenal gland (B.), and liver 
(C.) by H&E stain at 20X magnification.  Vhl2B/+ mice frequently developed renal 
(not shown) and adrenal (B., *) angiectasis and occasionally developed simple 
renal cortical microcysts (A., Cy).  E. – F. Histological analysis of ENU-
mutagenized Vhl2B/+ mice by H&E stain at 20X magnification.  While ENU 
mutagenesis promoted benign simple and papillary microcysts formation in both 
Vhl2B/+ (not shown) and wild-type littermates (D.), borderline 
adenoma/adenocarcinoma (E.) and adenocarcinoma (F.) were selectively 
observed in mutagenized Vhl2B/+ mice at twelve months.  Scale bars indicate 
100µm. 
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in wild-type littermates.  In contrast to prior studies, Vhl2B/+ liver histology was 
uniformly normal (Figure 3.8C).   
 Transplacental mutagenesis promotes renal tumorigenesis in Type 2B Vhl 
mice.  We hypothesized that accelerating somatic mutations via mutagenesis 
might reveal predisposition to cancer development in Vhl2B/+ mice.  ENU 
mutagenesis has traditionally been used as a tool to screen for dominant and 
recessive mutations in the mouse germline but has also been used in mouse 
adults and embryos.  ENU is a DNA alkylating agent which primarily generates 
A-T?T-A transversions and A-T?G-C transitions, most often resulting in 
missense mutations and splicing errors(277).  ENU is an ideal chemical for 
transplacental (in utero) renal mutagenesis: ENU does not require metabolic 
activation, the DNA repair enzymes responsible for repairing ENU lesions display 
low activity in the fetal kidney, and the fetal kidney is susceptible to mutagenesis 
in a wide range of embryonic days and ENU dosages (278).  Transplacental ENU 
mutagenesis has been utilized successfully in mouse models of another HIF-
related autosomal dominant tumor predisposition syndrome called Tuberous 
Sclerosis.  In mice heterozygous for a null allele of Tsc2 or Tsc1, transplacental 
ENU mutagenesis accelerates onset of renal cysts and hepatic angiomas (192, 
193).  Wild-type and Vhl2B/+ embryos from timed inter-heterozygous matings were 
treated with ENU at E14.5 and allowed to age to four (n=12) and twelve months 
(n=24) in a pilot study.  At sacrifice, grossly abnormal organs and organs of 
interest were harvested.  Renal lesions observed in mutagenized mice are 
summarized in Table 3.2 below. 
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Table 3.2. Summary of renal lesions observed in ENU-mutagenized Vhl2B/+ and 
wild-type littermates. 
 
 4 months 12 months 
Vhl +/+ 
(n=4) 
Vhl 2B/+ 
(n=8) 
Vhl +/+ 
(n=14) 
Vhl 2B/+ 
(n=10) 
Renal Microcyst(s)  3 6 11 7 
  -Papillary  3 1 2 1 
Pre-neoplasia  0 1 0 0 
Neoplasia  0 0 0 2 
 
 At four months, both wild-type (2/4) and Vhl2B/+ (6/8) mutagenized mice 
displayed macroscopic subpleural lung nodules, indicating successful ENU 
mutagenesis (279).  Both wild-type and Vhl2B/+ mutagenized mice displayed 
simple and papillary cortical renal microcysts on H&E-stained sections, 
suggesting that ENU mutagenesis effectively promotes benign renal cyst 
formation in this C57BL/6 genetic background.  While all three papillary renal 
cysts observed in mutagenized wild-type mice displayed benign histology, the 
papillary cyst in observed in a mutagenized Vhl2B/+ mouse displayed pre-
neoplastic changes (not shown).   
 At twelve months, histological findings in wild-type mutagenized mice were 
limited to benign papillary cysts (Figure 3.8D).  However, Vhl2B/+ mutagenized 
mice (2/10) developed pathological findings typical of VHL disease.  One Vhl2B/+ 
mouse developed a borderline clear-cell adenoma/adenocarcinoma (Figure 3.8E) 
featuring a large nest of cells (alveolus) with clear-cell histology, vascular stroma, 
and absent tubular architecture as well as several clear-cell alveoli invading into 
the underlying renal cortex.  A second affected Vhl2B/+ mouse developed 
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adenocarcinoma (Figure 3.8F) featuring nests of clear cells, central necrosis, 
absent tubular architecture, vascular stroma, and a poorly defined border.  
Statistical analysis suggested that Vhl mutation correlated with or trended toward 
development of neoplasia at 12 months (Pearson’s χ2 p=0.037, Fisher’s exact 
test p=0.101).   
Discussion 
 Germline Type 2B missense mutations in VHL predispose to ccRCC, CNS 
and retinal hemangioblastoma, and pheochromocytoma and paraganglioma.  In 
our murine gene replacement system, which models one VHL type 2B disease 
mutation, R167Q, generated a unique pattern of HIF-1α and HIF-2α 
dysregulation, differing from Vhl-null both in degree and ratio of HIF stabilization 
as well as in functional outcome in in vitro and in vivo studies.   
 Our gene replacement system takes advantage of the euploid genetic 
background of murine ES cells and avoids the potential mouse-human 
interactions and over- and mis-expression artifacts inherent to transgenic 
models.  We observed reduced levels of 2B mutant pVhl protein in homozygous 
ES cells, supporting the hypothesis that ccRCC-predisposing VHL missense 
mutations produce less stable proteins, as posited on the basis of structure 
analysis (55, 259).  In contrast to Vhl-/- ES cells, Vhl2B/2B knock-in ES cells 
expressed low basal levels of HIF-1α and HIF-2α and induced both subunits 
physiologically in response to the hypoxia mimetic CoCl2.  Consistent with this 
finding, Vhl2B/2B ES cells displayed wild-type levels of four HIF target genes 
studied,  suggesting that HIF-1α levels in Vhl2B/2B cells failed to surpass a 
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threshold required for transcriptional activation at target promoters in this cell 
type. 
 The differentiated teratoma system allowed observation of 2B mutant pVhl 
function in a setting permissive for both HIF-1α and HIF-2α transcriptional 
activity.  Previous work in Vhl-/- teratomas has demonstrated that maximal 
activation of both HIF-1α and HIF-2α promotes angiogenesis but retards three-
dimensional tumor growth (106).  Genetic knock-out of HIF-1α (280) or 
replacement of HIF-1α with HIF-2α (281) in teratomas enhances tumor growth 
and implicates HIF-1α as the growth-suppressive factor in this assay.   In our 
studies, Vhl-/- teratomas likewise displayed a growth disadvantage relative to 
wild-type and additionally featured over-expression of the joint HIF targets Vegfa 
and EglN3 and the HIF-1α-specific target Pfk1, all indicating HIF-1α and HIF-2α 
stabilization.  Vhl2B/2B teratomas, in contrast, displayed a marked growth 
advantage relative to wild-type, and over-expression of Vegfa and EglN3, but not 
Pfk1, suggestive of sub-threshold HIF-1α but sufficient HIF-2α stabilization to 
promote transcriptional activity.   
 The placental failure and lethality observed in Vhl2B/2B embryos at E9.5-
E10.5 was consistent with severely hypomorphic mutant pVhl function in the 
embryonic allantoic endothelium.  Reduced pVhl stability alone is unlikely to be 
the cause of Vhl2B/2B embryonic lethality.  First, 2B mutant pVhl levels in the E9.5 
Vhl2B/2B placenta were similar to pVhl levels observed in the E9.5 Vhl2B/+ placenta 
by IHC.  Second, VhlCP/CP mice are viable despite the measurable instability of 
R200W (CP) pVhl both in vitro and in murine tissues (112).  Finally, there is 
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evidence of more severe HIF dysregulation in this in vivo system, with evidence 
of induction of the HIF-1α-specific target Pfk1, indicating both HIF-1α and HIF-2α 
stabilization.  Thus, while it remains possible that the degree of pVhl reduction 
has a threshold effect on early developmental events, the reduced levels in these 
models serves to unmask added levels of regulation of the HIF transcriptional 
network. 
 Vhl2B/+ mice developed renal cysts with frequency similar to that observed 
in Vhl+/- mice (~3%) and likewise failed to develop dysplasia or renal 
adenocarcinoma, indicating that Vhl mutation alone is insufficient for invasive 
renal tumor formation in the murine kidney.  To accelerate the accumulation of 
somatic mutations in this mouse model and reveal tumor predisposition, we 
mutagenized Vhl-initiated and wild-type littermate mice with transplacental ENU.  
At twelve months post-ENU, renal adenocarcinoma was observed in 
mutagenized Vhl2B/+ mice, representing the first demonstration of this tumor in a 
genetically-predisposed mouse model and validating Vhl mutation as a tumor-
initiating event in the development of RCC.   
 Our gene replacement model of the representative Type 2B R167Q Vhl 
mutation bolsters emerging evidence that relative HIF-1α and HIF-2α protein 
abundance modulates the VHL Disease clinical phenotype and provides 
motivation for identifying the relevant genetic events involved in progressing Vhl-
initiated tumors to invasive disease.  More broadly, our Vhl gene replacement 
model provides a comprehensive species-congruent system for future 
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investigations of mutant pVhl HIF and non-HIF functions underpinning human 
VHL Disease both in vitro and in vivo.  
Materials and methods  
Generation of Vhl Type 2B ES cell lines and heterozygous mice.  Vhl 
exons 2 and 3 (E2 and E3) were cloned into targeting and mutagenesis vectors, 
respectively, from a BAC clone as previously described (112, 281).  PCR-based 
site-directed mutagenesis of G?A at position 518 was performed using forward 
primer 5’-AGAGCCTGGTCAAGCCTGAGAACTA-3’ and reverse primer 5’-
GCACAACCTGAAGGCACCGCTCTTT-3’.  The G518A mutant E3 fragment was 
then cloned into pLNT-E2 adjacent to the neoR cassette (pLNT-E2-E3) and 
reconfirmed with bidirectional sequencing.   
The pLNT-E2-E3 targeting construct (Figure 3.1B) was electroporated into 
Vhl wild-type J1 strain Sv/129 ES cells for gene replacement at the endogenous 
murine Vhl locus.  Homologous recombinants heterozygous for the Vhl2B neo-in 
allele were selected by gancyclovir and neomycin resistance, and positive clones 
confirmed by Southern blot analysis.  Conversion of the second Vhl allele was 
achieved by selection with increasing amounts of neomycin to yield ES cells 
homozygous for the Vhl2B neo-in allele.  Vhl2B neo-in/+ and Vhl2B neo-in/2B neo-in ES cells 
were transiently transfected with a cre-expressing vector to remove the floxed 
neoR cassette.  The ES cells were screened at each stage by Southern blot for in 
vitro and in vivo studies of Type 2B mutant pVhl function. 
 105 
 
Animal Models Core (University of Pennsylvania) staff injected karyotyped 
Vhl2B neo-in/+ ES cells into C57BL/6 blastocysts.  The chimeric blastocysts were 
then implanted in pseudopregnant C57BL/6 females.  Highly chimeric mice (F0) 
were selected by Agouti coat color for crossing to C57BL/6 females.  Germline 
transmission of the targeted allele to Agouti offspring (F1) was confirmed by 
Southern blot.  A Vhl2B neo-in/+ line was crossed to a cre deleter mouse strain (EIIa-
cre) (282) for multiple generations, with excision of the floxed neoR cassette 
verified by Southern blot, and then backcrossed to C57BL/6 to make a Vhl2B/+ 
founder line.  All subsequent generations were genotyped by restriction PCR 
utilizing PCR primers flanking a novel HpyIV restriction site introduced by the 
G518A Vhl mutation (Figure 3.1D).   
All mouse procedures were approved by the University of Pennsylvania 
and University of North Carolina Institutional Animal Care and Use Committees.   
Cell Culture Studies.  Cell culture studies were performed at 37ºC, 5% 
CO2. ES cell lines were maintained in ES media consisting of high glucose 
Dulbecco’s Modified Eagle Medium (Gibco, Carlsbad, CA, USA) supplemented 
with 5% fetal bovine serum, L-glutamine, β-mercaptoethanol, non-essential 
amino acids, and leukemia inhibitory factor (LIF), and grown on gelatin-coated 
tissue culture-grade plates (Corning, Corning, NY, USA).  For chemical hypoxia 
mimetic experiments, cells were grown in the presence or absence of CoCl2 (100 
µM) for four hours.  For proteasome inhibition experiments, cells were treated 
with vehicle (DMSO) or MG-132 (5 µM, Calbiochem, San Diego, CA, USA) for 
four hours. 
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In vitro differentiation studies were performed as previously described 
(283).  Briefly, overgrown undifferentiated ES cells were re-plated in 
differentiation media (ES media without LIF) on non-tissue culture-treated plates 
and allowed to differentiate in suspended culture into embryoid bodies over a 
three-day period.  Embryoid bodies were then transferred at low density to tissue 
culture-grade plates, permitting attachment, and allowed to differentiate for an 
additional eight days.  Both suspended and attached cultures were fed with 
differentiation media every two days.  Fully-differentiated attached cultures were 
briefly fixed in ice-cold methanol/acetone (1:1) and subjected to staining with 
primary rat anti-mouse PECAM (MEC 13.3, BD Pharmingen, San Diego, CA, 
USA) and secondary TRITC-conjugated donkey anti-rat IgG (Jackson 
Immunoresearch, West Grove, PA, USA) for immunofluorescent visualization of 
endothelial cells and primitive vascular morphology. 
For in vivo teratoma studies, undifferentiated ES cells of each genotype (5 
x 106) were injected subcutaneously into the flanks of nu/nu mice (Taconic Labs, 
Hudson, NY, USA) and allowed to grow for six weeks with weekly caliper 
measurements of tumor size.  Harvested tumors were bisected and either flash-
frozen in liquid nitrogen for molecular analysis or formalin-fixed and paraffin-
embedded for histological analysis. 
Molecular analysis of Vhl, HIF, and HIF targets.  Whole-cell protein 
extracts or fresh extracts from teratomas harvested six weeks post-injection were 
prepared for immunoblot in NET lysis buffer (20mM Tris, 100mM NaCl, 1mM 
EDTA, 1% NP-40) and quantitated by Bradford assay.  Immunoblot primary 
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antibodies used were: pVhl (M20 and FL181, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), HIF-1α (10006421, Cayman Chemical, Ann Arbor, MI, USA and 
(284)), HIF-2α (NB100-122, Novus Biologicals, Littleton, CO, USA), and eEF2 
(Cell Signaling Technology, Danvers, MA, USA).  Murine Vegf ELISA was 
performed on conditioned medium from cultured ES cells (R & D Systems, 
Minneapolis, MN, USA). 
RNA isolation from ES cells, teratomas, and E9.5 embryos was performed 
using the RNeasy Mini system according to manufacturer’s instructions (Qiagen, 
Germantown, MD, USA) and quantified by UV spectroscopy.  cDNA was 
prepared from 0.5µg of RNA using Superscript reverse transcription reagents 
(Stratagene, Cedar Creek, TX, USA).  Quantitative RT-PCR was performed in 
triplicate using stock commercial primer-probe sets for Vhl, Vegfa, Glut1, EglN3, 
Pfk1, and 18S ribosomal subunit according to manufacturer’s instructions 
(Applied Biosystems, Foster City, CA, USA).  A candidate screen for teratoma 
hemangioma-associated genes was performed in triplicate on the RT2 Profiler 
Mouse Angiogenesis Array using cycle parameters according to manufacturer’s 
instructions (SABiosciences, Frederick, MD, USA).  Genes identified for further 
validation were analyzed by quantitative RT-PCR in triplicate using stock 
commercial primer-probe sets for Cdh5, Eng, Kdr, Nrp1, Vegfc, and 18S 
ribosomal subunit and cycle parameters according to manufacturer’s instructions 
(Applied Biosystems).   All quantitative RT-PCR output raw cycle thresholds were 
normalized to the internal 18S ribosomal RNA standard. 
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Densitometric analysis of HIF immunoblots.  HIF-1α and HIF-2α 
experimental immunoblots, along with corresponding actin and eEF2 loading 
control immunoblots, were obtained on whole-cell protein extracts from untreated 
or cobalt chloride-treated ES cells as described in primary Materials and Methods 
section.  Densitometry was performed on scanned immunoblot images using the 
ImageJ gel analysis tool (285).  The gel analysis tool was used to obtain the 
absolute intensity (AI) for each experimental HIF band and corresponding control 
band.  Relative intensity (RI) for each experimental band was calculated by 
normalizing the experimental AI to the corresponding control AI.   
Embryonic lethality and transplacental ethyl nitrosourea (ENU) 
mutagenesis studies.  Vhl2B/+ mice were set up for timed inter-heterozygous 
mating.  Embyronic day (E) 0.5 was defined as noon on the day the vaginal plug 
was observed, and embryos and placentas were harvested at E9.5 and E10.5.  
For placental studies, embryos were examined for gross defects and genotyped 
by restriction PCR, and placentas were processed for histological examination.  
For embryonic studies, E9.5 embryos were used for both RNA extraction and 
genotyping by restriction PCR.   
For transplacental mutagenesis studies, intraperitoneal (i.p.) injection of 
50 mg/kg ENU (Sigma, St. Louis, MO, USA) dissolved in ethanol was 
administered to the pregnant dam at E14.5 (192).  Mutagenized Vhl2B/+ and wild-
type littermates were aged in four- and twelve-month cohorts and sacrificed for 
gross and histological examination.   
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Histological analysis of murine tissues.  Harvested tissues were fixed in 
10% buffered formalin.  Paraffin-embedded tissues were sectioned and stained 
with hematoxylin and eosin (H&E) or for pVhl (FL181) or Vegfa (VG-1, Santa 
Cruz).  
Statistical analysis.  A two-tailed Student’s t test was used to make paired 
comparisons for quantitative RT-PCR and Vegf ELISA data.  A value of p≤0.05 
was used as the threshold for statistical significance.  Pearson’s χ2 test and 
Fisher’s exact test were used to compare development of neoplasia in wild-type 
versus Vhl-mutant mutagenized mice. 
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Chapter Four 
Summary, Discussion, Future Directions, and Conclusion 
Summary 
R167Q HA-VHL assembles into a ubiquitin ligase complex with activity 
towards HIF-α.  Biallelic loss of the von Hippel-Lindau (VHL) tumor suppressor 
gene is a nearly universal feature of sporadic clear cell renal cell carcinoma 
(ccRCC).  Germline mutations in VHL likewise predispose to development of 
tumors including retinal and CNS hemangioblastoma, pheochromocytoma, and 
ccRCC in a genotype-specific manner.  I have chosen to focus my dissertation 
work on the representative hotspot Type 2B VHL mutation R167Q which confers 
risk for all three VHL Disease-associated tumors.   
We have previously shown that over-expression of HA-tagged human 
R167Q VHL protein (pVHL) rescues HIF-1α but not HIF-2α normoxic 
suppression in Vhl-/- murine embryonic stem (ES) cells(107), despite structural 
predictions that the R167Q mutation disrupts pVHL recruitment of Elongin C and 
thereby recruitment of the remaining VBC ubiquitin ligase complex members 
Elongin B, CUL2, and ROC1 (Rbx1)(56-59).   In an effort to elucidate the 
mechanism behind the observed partial retention of HIF-α regulation, we studied 
the structure and function of the VBC complex in Vhl-/- J1 murine ES cells and 
VHL-/- 786-0 human RCC cells complemented with wild-type human HA-tagged 
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VHL or mutant HA-tagged VHL representing each subtype of human VHL 
Disease(247).    
We first examined wild-type and mutant VBC structure by co-
immunoprecipitation immunoblot analysis of HA-VHL with known complex 
members.  We were unable to detect co-immunoprecipitation (IP) of Elongin C 
with R167Q HA-VHL in transgenic murine ES cells as predicted and previously 
shown(107) but, surprisingly, found that R167Q HA-VHL retained binding with 
Cul2 and Rbx1.  In order to rule out potential artifacts of mouse-human 
interaction, we confirmed our results in the equivalent complemented 786-0 cell 
line.  We showed that 786-0 + R167Q HA-VHL cells retained partial normoxic 
suppression of HIF-2α.  We also again found that R167Q HA-VHL failed to 
interact with Elongin C but retained interaction with CUL2 and ROC1.  We were 
able to replicate this result by co-IP of CUL2 with a second representative Type 
2B mutant HA-VHL, D121G, and by reverse co-IP of R167Q HA-VHL with myc-
tagged CUL2.  We next assessed the function of R167Q VBC with an in vitro 
ubiquitylation assay (modified from (63)).  786-0 cell extracts (vector only or wild-
type or mutant HA-VHL) were incubated with in vitro-transcribed HIF-1α and a 
defined reaction solution and then subjected to HIF-1α immunoblot in order to 
detect an upward shift in HIF-1α molecular weight indicative of ubiquitination.  
We found that R167Q HA-VHL permitted wild-type ubiquitylation of HIF-1α in 
vitro.   
In summary, we have shown that R167Q HA-pVHL assembles into a VBC 
ubiquitin ligase complex with activity towards HIF-α.  We postulate that R167Q 
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HA-VHL retains a transient association with Elongin C and/or maintains contact 
with CUL2 via a novel interaction with an alternate Cullin/adaptor pair. 
A mouse-specific gene replacement model of Type 2B VHL Disease.  
Having shown that Type 2B mutant R167Q pVHL is capable of directing HIF-α 
ubiquitylation when over-expressed in a VHL-deficient RCC-derived cell line, we 
endeavored to address the function of R167Q pVHL expressed under 
endogenous control using a comprehensive gene replacement (knock-in) mouse 
model of Type 2B VHL Disease(263).  The R167Q missense mutation (G518A) 
was targeted to the endogenous wild-type Vhl locus in J1 murine ES cells, 
generating Vhl2B/+ and Vhl2B/2B ES cells for comparison to Vhl-/- and parental Vhl+/+ 
J1 ES cells.  The panel of ES cells was used directly for studies of pVhl, HIF, and 
HIF target gene expression and in an in vivo teratoma assay for tumor growth.  
Vhl2B/+ ES cells were used to generate knock-in mice for timed mating studies of 
murine development and aging studies of tumor predisposition. 
We first analyzed the pVhl/HIF axis in the panel of 2B ES cells.  While the 
2B Vhl allele was expressed at wild-type levels by quantitative RT-PCR, the 2B 
mutant pVhl was present at greatly reduced levels relative to wild-type pVhl.  
Despite hypomorphic expression of 2B pVhl, Vhl2B/2B ES cells retained near-
normal normoxic suppression of HIF-α (HIF-1α > HIF-2α) and normal hypoxia 
mimetic-induced HIF-α stabilization.  Vhl2B/2B ES cells, furthermore, appropriately 
suppressed a panel of HIF target genes including the joint HIF targets Vegfa, 
EglN3, and Glut1 and the HIF-1α-specific target Pfk1 under normoxic conditions 
by quantitative RT-PCR.  Vhl-/- ES cells, in contrast, over-expressed all four HIF 
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target genes.  Because HIF-2α is expressed but not transcriptionally active in J1 
ES cells, the lack of normoxic HIF target gene expression in Vhl2B/2B ES cells 
indicates insufficient HIF-1α levels. 
We next examined 2B mutant pVhl function in an in vivo teratoma assay.  
Teratomas were generated from ES cells of each genotype injected into the 
flanks of nude mice and followed over the course of six weeks.  Vhl-/- ES cell-
derived teratomas displayed a growth disadvantage relative to J1-derived 
teratomas, confirming earlier work in the lab(107).  Surprisingly, however, Vhl2B/2B 
teratomas displayed a growth advantage relative to J1.  By gross examination, 
Vhl2B/2B teratomas were markedly hemorrhagic and by histological examination 
displayed enhanced hemangioma formation relative to Vhl-/-.  As both HIF-1α and 
HIF-2α are expressed and transcriptionally active in teratomas, we next 
examined HIF target gene expression by quantitative RT-PCR.  Vhl-/- teratomas 
over-expressed Vegfa, EglN3, and Pfk1 relative to J1.  Vhl2B/2B teratomas over-
expressed Vegfa and EglN3 but not Pfk1, suggestive of sufficient HIF-2α but 
insufficient HIF-1α stabilization to direct target gene expression.  As HIF-1α has 
been shown to be growth-suppressive and HIF-2α has been shown to be growth-
promoting, we postulate that enhanced Vhl2B/2B teratoma growth results from 2B 
mutant pVhl-associated maximal HIF-2α and sub-maximal HIF-1α stabilization.  
Because differences in Vegfa expression alone could not account for the 
dramatically enhanced hemangioma formation observed in Vhl2B/2B teratomas 
relative to Vhl-/-, we used an RT2 Profiler quantitative RT-PCR array to query 84 
angiogenesis-related genes for association with the hemangioma phenotype in 
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teratomas.  Six angiogenesis-related genes, including Vegfa, screened positive 
as significantly over-expressed in Vhl-/- and/or Vhl2B/2B relative to J1 teratomas.  
The five novel genes were validated using independent primers.  Briefly, Vhl-/- 
and Vhl2B/2B teratomas were confirmed to over-express Cdh5 (VE-cadherin), Kdr 
(VegfR2), and Eng (endoglin).  In addition, Vhl2B/2B teratomas uniquely over-
expressed Nrp1 (neuropilin-1).   
We next compared Vhl-/- and Vhl2B/2B to J1 ES cells in an in vitro vascular 
differentiation assay.  Briefly, ES cells were allowed to differentiate into spherical 
tri-laminar embryoid bodies in suspended culture for three days.  Embryoid 
bodies were then grown in attached culture conditions to encourage vascular 
differentiation, as visualized by PECAM immunofluorescent stain.  J1-derived 
embryoid bodies sprouted a network of well-formed primitive vessels with 
branching at regular intervals, while Vhl-/- embryoid bodies differentiated into 
PECAM+ cells but failed to sprout primary vessels.  Vhl2B/2B embryoid bodies 
displayed an intermediate phenotype, differentiating into a disorganized network 
defined by haphazard sprouting.  These results suggest that the enhanced 
hemangioma formation observed in Vhl2B/2B teratomas relative to Vhl-/- may derive 
from an imbalance in Vegfa signaling in association with an exuberant, if 
aberrant, vascular potential.  
Finally, we examined Type 2B mutant pVhl function in murine 
development and tumor predisposition using Vhl2B/+ knock-in mice derived from 
Vhl2B/+ murine ES cells.  Timed inter-heterozygous matings revealed the 2B Vhl 
allele to be homozygous lethal at E9.5-10.5.  Coupled with the grossly normal 
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embryo at E9.5 and the fact that Vhl-/- embryos die at approximately E10.5 from 
defective placental labyrinthine vascularization, we examined the histology of 
Vhl2B/2B placentas.  While wild-type and Vhl2B/+ placentas at E9.5 showed allantoic 
vascular invasion of the chorionic plate in the presumptive labyrinth, allantoic 
vessels failed to invade the chorionic plate in Vhl2B/2B placentas, pointing to a 
severely hypomorphic role for the 2B Vhl allele in murine development.  
Quantitative RT-PCR for our panel of HIF target genes failed to reveal any 
differences between Vhl2B/+ and Vhl2B/2B E9.5 placentas due to the relatively large 
contribution of maternal decidua to the placenta at that time-point.  We did find, 
however, that Vhl2B/2B E9.5 embryos over-expressed all four HIF target genes 
compared to Vhl2B/+ littermates.  The stabilization of HIF-1α +/- HIF-2α in Vhl2B/2B 
E9.5 embryos could be due to mutant 2B pVhl activity and/or pathophysiological 
hypoxia due to the failing placenta.   
We next used Vhl2B/+ mice for aging studies of tumor predisposition.  
Similar to mice heterozygous for a Vhl-null allele, Vhl2B/+ mice developed rare 
renal microcysts (3%), no renal adenocarcinoma, and frequent adrenal and renal 
angiectasis.  In dramatic contrast to Vhl-null models, however, Vhl2B/+ mice did 
not develop hepatic angiomas, pointing to a missense mutation-specific alteration 
in the spectrum of susceptible tissues. 
In order to determine whether Vhl initiation could predispose mice to 
development of renal tumors, I modeled the accumulation of somatic mutations 
using in utero mutagenesis with ENU (50 mg/kg IP to pregnant dam at E14.5).  In 
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a small pilot study, mutagenized Vhl2B/+ and mutagenized wild-type littermates 
were aged to four and twelve months and assessed for tumor predisposition. 
Both Vhl2B/+ and wild-type mutagenized mice had developed simple and 
papillary renal cysts at four and twelve months.  At twelve months, however, 2/10 
mutagenized Vhl2B/+ mice developed renal adenocarcinoma, representing the first 
demonstration of this tumor in a genetically predisposed mouse model.  Step 
serial sections of kidneys from wild-type mutagenized mice failed to reveal any 
neoplastic changes.  In summary, we have shown that the representative R167Q 
2B mutant pVhl generates a unique profile of HIF-1α and HIF-2α stabilization 
with dramatic effects on three dimensional tumor growth and tissue susceptibility 
to tumorigenesis. 
Discussion 
HIF-α accumulation is a central feature of renal tumorigenesis. Inactivating 
mutations in the tumor suppressors BHD, TSC1, or TSC2 and activating 
mutations in the proto-oncogene MET contribute to HIF-α accumulation by 
enhancing translation through the mTOR pathway, while inactivating mutations in 
VHL, FH, and SDHB promote HIF-α stabilization by permitting HIF-α to evade 
oxygen-dependent regulation.  Renal tumors arising in patients with germline 
mutations in these genes display accumulation of both HIF-1α and HIF-2α, 
though HIF-2α predominates in VHL-, BHD-, and MET/HPRC-associated RCC 
and HIF-1α predominates in FH/HLRCC-associated RCC.  The penetrance, 
histology, and clinical course associated with RCC predisposition in each of 
these inherited syndromes likely derives from the dosage or relative ratio of HIF-
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1α and HIF-2α accumulation as well as HIF-independent factors specific to each 
genetic lesion. 
HIF-α stabilization is not an all-or-nothing phenomenon.  The 
representative Type 2B VHL mutant R167Q produces a unique profile of HIF-α 
stabilization in comparison to both wild-type, null, and other VHL Disease-
associated mutant VHL proteins.  Wild-type J1 murine ES cells suppress while 
Vhl-null murine ES cells maximally stabilize both HIF-1α and HIF-2α under 
normoxic conditions.  Vhl-null ES cells complemented with the representative 
Type 2A VHL mutant Y112H display wild-type normoxic suppression of HIF-1α 
but dose-dependent suppression of HIF-2α.  Finally, Vhl-null ES cells 
complemented with the representative Type 2B VHL mutant R167Q display wild-
type normoxic suppression of HIF-1α but impaired normoxic suppression of HIF-
2α (Ref Rathmell 2004).  ES cells homozygous for a gene replacement allele for 
R167Q likewise displayed normal normoxic suppression of HIF-1α but 
stabilization, though sub-maximal, of HIF-2α.   
We have elucidated one potential mechanism for the intermediate HIF-α 
stabilization profile associated with Type 2B VHL mutants: the assembly of a 
remnant VBC complex.  Despite an absent or drastically reduced capability to 
bind Elongin C, both R167Q and a second representative Type 2B VHL mutant 
D121G retain interaction with VBC complex members CUL2 and ROC1 in 
complemented VHL-null 786-0 RCC cells.  Furthermore, cell extract from R167Q 
HA-VHL-expressing cells retains the ability to direct ubiquitylation of HIF-α in an 
in vitro assay.  These results suggest that R167Q pVHL assembles into a 
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remnant VBC complex, either containing Elongin C in reduced amounts or 
bypassing the requirement for Elongins C and B entirely by directly interacting 
with CUL2 or interacting with CUL2 via a second cullin-adaptor pair.   
In a structural homology threading model of the VBC complex based on 
the solved crystal structure of the related yeast SCF complex, we have shown 
that VHL is indeed likely to bind directly with CUL2, though the small interface 
between the two is unlikely to be a stabilizing factor in the absence of Elongins C 
and B (data not shown, Brian Kuhlman, UNC).  In addressing the latter 
possibility, we have thus far been unable to detect an interaction between R167Q 
mutant pVHL and CUL1-SCF1 or CUL4-DDB1, though interaction with CUL3 and 
any number of BTB-domain adaptors remains a possibility.   
The stability of the mutant pVHL likely influences both its ubiquitin ligase-
dependent and –independent functions.  In the HA-VHL-complemented ES cell 
and 786-0 cell systems used in the above studies, clones expressing near wild-
type levels of R167Q HA-VHL were used in experiments of VBC structure and 
function.  In murine ES cells, however, the Type 2B mutant R167Q pVhl is 
expressed at greatly reduced levels compared to wild-type pVhl.  
Imbalances in HIF-α family members contribute to differences in disease 
biology.  Sporadic ccRCC tumors expressing both HIF-1α and HIF-2α (H1H2) 
differ significantly from those expressing HIF-2α alone (H2)(286).  In a recent 
study, 57 independent sporadic ccRCC tumors were classified as VHL WT 
(neither HIF-1α nor HIF-2α detected, 12%), H1H2 (61%), or H2 (27%) by HIF 
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immunostaining.  VHL inactivation by mutation, deletion, or promoter methylation 
was confirmed in 49/50 H1H2 and H2 ccRCC tumors.  Consistent with earlier 
studies suggesting that HIF-2α enhances and HIF-1α tends to oppose c-Myc 
activity, H2 tumors displayed enhanced c-Myc activation and  proliferation (55% 
increase in Ki67 positivity) and reduced genomic copy number changes (40% 
decrease) in comparison to VHL WT and H1H2 tumors.  In contrast, VHL WT 
and H1H2 tumors uniquely displayed activation of the AKT/mTORC1 (phospho-
S6) and MAPK/ERK (phospho-ERK) pathways.  Intriguingly, both in vivo studies 
on ccRCC tumors and in vitro studies utilizing HIF-1α and HIF-2α knock-down in 
RCC cell lines suggested that H2 tumors stimulate DNA repair by enhancing 
expression of homologous recombination effectors, thereby limiting G1/S 
checkpoint activation.  Overall, these studies suggest that ccRCC tumors 
characterized by HIF-2α stabilization correlates with c-Myc activation and 
efficient transit through S phase, while ccRCC tumors characterized by 
stabilization of both HIF-1α and HIF-2α correlate with growth factor signaling 
through AKT/mTORC1 and MAPK/ERK. 
Studies of the VHL/HIF pathway in teratoma models suggest that the 
profile of HIF-α stabilization directly influences tumor growth and angiogenesis.  
Teratomas generated from HIF-1α-/- murine ES cells display poor vascularization, 
reduced hemangioma formation, and similar early growth (through week three) 
but enhanced delayed growth (weeks four through seven) in comparison to 
transgenic HIF-1α-rescued ES cells(280).  The growth phenotype transition at 
three weeks, together with the observation of three-fold more hypoxic zones in 
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comparison to HIF-1α-rescued, suggests that physiological hypoxic stabilization 
of HIF-2α played a role.  Teratomas derived from ES cells in which a HIF-2α 
allele replaces endogenous HIF-1α (HIF-2αKI/KI, also functionally HIF-1α-/-) 
display more rapid growth, greater hemorrhage and mass, increased vessel 
density, and increased hemangioma formation relative to wild-type 
teratomas(281).  Altogether, these studies suggest that HIF-2α stabilization is 
tumor growth-promoting and that HIF-1α is growth-suppressive.  As evidenced by 
the HIF-2αKI/KI model, teratoma hemangioma formation appears to depend not 
upon HIF-1α expression specifically but more generally on HIF-1α locus-specific 
control, perhaps directing a specific temporal and/or spatial context for HIF-α 
expression. 
Teratomas derived from Vhl-/- ES cells, predicted to maximally stabilize 
both HIF-1α and HIF-2α, display reduced growth but enhanced hemangioma 
formation relative to wild-type teratomas(106, 107).  Teratoma growth and 
hemangioma suppression were completely rescued by wild-type HA-VHL, while 
the representative Type 2B VHL mutant R167Q HA-VHL rescued teratoma 
growth but not hemangioma suppression(107).  Surprisingly, Vhl2B/2B teratomas 
grow more rapidly than both Vhl-/- and J1 and display enhanced hemangioma 
formation relative to Vhl-/-.  We suspect the differences in tumor growth and 
hemangiogenesis in teratomas derived from Vhl-/- + R167Q HA-VHL and those 
derived from Vhl2B/2B ES cells arise from hypomorphic expression of 2B mutant 
pVhl from the endogenous locus and a resulting shift in the HIF-α profile.  In 
addition to a growth profile consistent with enhanced HIF-2α stabilization, Vhl2B/2B 
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teratomas fail to stabilize sufficient HIF-1α to activate transcription of the HIF-1α-
specific target Pfk1.  The severity of the 2B Vhl allele in this three-dimensional 
tumor model suggests that a HIF balance shifted towards HIF-2α may promote 
better tumor growth than maximal stabilization of both HIF-1α and HIF-2α. 
R167Q pVhl is associated with a unique pattern of angiogenesis-related 
gene expression.  Vhl2B/2B teratomas display greatly enhanced hemangioma 
formation relative to Vhl-/- teratomas despite over-expressing an equivalent 
amount of Vegfa.  In an effort to generate hypotheses about the genes involved 
in the hemangioma phenotype, we compared the expression of 84 angiogenesis-
related genes in Vhl2B/2B and Vhl-/- relative to J1 wild-type teratomas.  We found 
that both Vhl2B/2B and Vhl-/- teratomas over-expressed Vegfa, Kdr, Cdh5, and 
Eng, but Vhl2B/2B teratomas uniquely over-expressed Nrp1 as well.  Kdr and Nrp1 
are both involved in Vegfa signaling, encoding, respectively, the Vegfa receptor 
VegfR2 and its co-receptor neuropilin-1.  Neuropilin-1 has been shown to 
enhance isoform-specific Vegfa signaling through VegfR2(287).  
In an independent approach, we tested the in vitro vascular differentiation 
potential of Vhl2B/2B and Vhl-/- relative to J1 wild-type ES cells in an embryoid 
body assay.  We found that J1-derived embryoid bodies sprouted a well-formed 
vascular plexus of PECAM+ cells, Vhl-/--derived embryoid bodies appeared to 
proliferate but did not sprout vessels, and Vhl2B/2B-derived embryoid bodies 
developed an intermediate phenotype of a robust but disorganized vascular 
network.  Studies of the Vegfa signaling pathway in this in vitro embryoid body 
vascular differentiation system indicate that the balance of endothelial 
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proliferation versus generation of vessels is exquisitely sensitive to the absolute 
and relative dosages of critical individual pathway components such as VegfR2, 
VegfR1, and Vegfa(288-290).  The importance of dosage in Vegfa signaling is 
underscored in vivo by the haplo-insufficient embryonic lethality observed in 
Vegfa+/- mice(291, 292).  The results of the in vitro vascular differentiation assay 
and the hemangioma-related gene signature of Vhl2B/2B versus Vhl+/- teratomas 
suggest that the 2B mutant pVhl does indeed promote tumor hemangioma 
formation, perhaps via HIF-dependent or mutant pVhl-dependent effects on 
Vegfa signaling.  
The discovery of a mutant 2B pVhl-specific hemangioma-associated gene 
profile warrants further study for its implications in renal tumor biology and in 
human VHL Disease.  In order to address the former, we are currently 
developing a primary renal tubule epithelial cell culture system designed to 
permit dissection of HIF- and mutant pVhl-dependent effects on tumorigenic 
potential, three-dimensional tumor growth and vascularity, and gene expression.  
This system is described in detail below.  In order to address the latter, we are 
collaborating with a rare-disease tissue bank in order to obtain ccRCC and 
adjacent normal tissue from VHL Disease patients with Type 1, Type 2A, and 
Type 2B VHL mutations.  These tissues will be used to define missense 
mutation-specific gene expression profiles for correlation with clinical history and 
histopathological features. 
A gene replacement model of Type 2B VHL phenocopies the null allele in 
embryonic development but changes target tissue spectrum.  Vhl2B/2B embryos 
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die at E9.5-10.5 with a placental phenotype consistent with the phenotype 
reported for Vhl-null.  At E10.5, Vhl-/- placental labyrinths display reduced fetal 
vessel content and, as a consequence, separation of the maternal and fetal 
circulations (110).  At E9.5, the latest time-point we could examine histologically, 
Vhl2B/2B placentas display reduced fetal vessel invasion into the chorionic plate, a 
defect which would presumably manifest as reduced fetal vascularization of the 
labyrinth 1-2 days later if the embryos had survived.  The Vhl-/- labyrinthine defect 
has been localized to Vhl deficiency in the embryonic endothelial 
compartment(132).  Though we observed over-expression of both joint HIF 
targets and the HIF-1α specific target Pfk1 in whole Vhl2B/2B embryos relative to 
Vhl2B/+ embryos at E9.5, this HIF target gene expression most likely reflects 
physiological hypoxia near associated with embryonic death and is unlikely to 
capture the absolute dosage and relative stabilization of HIF-α factors due to 
genetic loss of Vhl in the relevant endothelial compartment.    
Though Vhl heterozygous-null mice develop hepatic angiomas with 
moderate to dramatic, age- and genetic background-dependent penetrance, 
Vhl2B/+ mice never developed hepatic angiomas.  Though genetic background 
may have conferred a degree of resistance to hepatic angioma formation in our 
mouse model – the penetrance of hepatic angioma in Vhl+/- mice on the C57BL/6 
is a modest 18% at 12 months – we suspect that the lack of hepatic angiomas 
derives from a 2B missense mutation-specific effect on HIF-α stabilization.  
Addressing the former, our lab has independently shown that Vhlf/f injected with 
Adenoviral-cre recombinase develop hepatic angiomas with high penetrance, 
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while Adeno-cre-injected Vhl2B/f mice do not develop hepatic angiomas (Shufen 
Chen).  Addressing the latter, hepatocytic HIF-2α stabilization has been shown to 
be both necessary in the context of Vhl loss (134) and independently sufficient 
(135) to generate hepatic angiomas.  Thus, the lack of hepatic angioma 
formation observed in Vhl2B/+ mice is likely to result primarily from insufficient 
HIF-2α stabilization in hepatocytes. 
Our mouse model of Type 2B VHL Disease emphasizes the tissue- and/or 
context-dependent effect of R167Q mutant pVhl on HIF-α stabilization.  First, the 
2B Vhl allele confers greater HIF-2α than HIF-1α stabilization in association with 
enhanced tumor growth and hemangioma formation in a three-dimensional tumor 
growth model.  Second, the 2B Vhl allele appears to phenocopy the Vhl null 
allele in contribution of the embryonic endothelium to the placental labyrinth in 
development.  Finally, the 2B Vhl allele confers a reduction in hepatic angioma 
formation in the adult mouse likely attributable to sub-threshold HIF-2α 
stabilization. 
Vhl mutation predisposes to renal tumorigenesis subsequent to 
mutagenesis.  Though rats develop both spontaneous and inherited renal 
adenocarcinomas, thus far genetic targeting of loci associated with human renal 
tumor predisposition syndromes has failed to recapitulate RCC in the mouse.  
PEPCK-cre;Vhlf/f mice develop renal cysts with modest penetrance and long 
latency(136).  Addition of a second genetic event, Pten loss, results in a highly 
penetrant renal cyst phenotype with short latency in Ksp1.3-cre;Vhlf/f mice, but 
the associated progressive renal failure prevented assessment of tumor 
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predisposition after 3-6 months(140).  These mouse models suggest that the 
generation of renal cysts in Vhl-initiated mice requires at least one additional 
genetic event but do not indicate whether Vhl initiation of renal cysts is a requisite 
step in the progression to renal adenocarcinoma or whether Vhl initiation of renal 
adenocarcinoma occurs via an independent or bifurcated path. 
In an effort to determine whether Vhl-initated mice could be pushed to 
develop renal adenocarcinoma, we modeled the accumulation of somatic 
mutations in Vhl2B/+ mice using transplacental ENU mutagenesis.  ENU was 
equally renal cystogenic in Vhl2B/+ and wild-type littermate controls at four and 
twelve months.  At twelve months, however, 2/10 mutagenized Vhl2B/+ mice and 
0/14 mutagenized wild-type mice developed renal adenocarcinoma with clear 
cells and vascular stroma reminiscent of human ccRCC.  We believe this is the 
first demonstration of renal adenocarcinoma in a genetically predisposed mouse. 
Future Directions 
Type 2B VHL mutations predispose to the full spectrum of VHL disease-
associated tumors and are additionally postulated to foster more aggressive 
renal tumors than Type 1 and Type 2A VHL mutations.  Our lab has undertaken 
both in vitro and in vivo approaches to examine the tumor-promoting activities of 
a representative hotspot Type 2B VHL mutation, R167Q.  We have demonstrated 
that xenografts expressing human Type 2B VHL cDNA (107) and teratomas 
homozygous for the equivalent murine Type 2B Vhl mutation (263) grow more 
rapidly than the corresponding Type 1 tumors.  Our gene replacement mouse 
model of Type 2B VHL disease, furthermore, is the first Vhl model to 
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demonstrate a predisposition for renal adenocarcinoma (263).  Together with our 
in vitro findings that Type 2B VHL retains intermediate ubiquitin ligase activity 
towards hypoxia inducible factor (HIF)-α (247), our in vivo studies suggest that 
the maximal HIF stabilization conferred by Type 1 VHL mutations is detrimental 
to tumor growth.   
We propose to study the interplay of Vhl Type 2B mutation or loss and 
HIF-α stabilization by generating renal epithelial and dermal fibroblast primary 
cell cultures from our existing Type 2B Vhl mouse strain, a conditional Vhl 
deletion strain, and conditional transgenic strains encoding stable HIF-1α and 
HIF-2α.  We hypothesize that Type 2B VHL mutation generates a profile of 
relative and absolute HIF-1α and HIF-2α levels that activates a unique subset of 
the total HIF target gene repertoire.  Our proposed primary cell culture-based 
system models Vhl mutation, Vhl loss, and HIF stabilization in a euploid epithelial 
setting similar to the native kidney in early renal tumorigenesis and is highly 
tractable for functional and molecular studies of VHL Disease-associated 
phenotypes.  
First, cell culture and allograft growth of Vhl 2B/flox cells will be compared 
with Vhl flox/flox cells and cells with Vhl-independent HIF stabilization.   A panel of 
primary cell cultures will be developed from newborn kidneys and skin from Type 
2B, conditional Vhl-null, and conditionally stabilized HIF mice and exposed to 
viral cre in culture.  Tumorigenic potential in vitro will be assessed by cellular 
doubling time, duration of continuous culture, growth in soft agar, and formation 
of primary cilia.  Tumorigenic potential in vivo will be assessed by implanting cells 
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subcutaneously or orthotopically in nude mice to study tumor growth, histology, 
and invasiveness.  
Secondly, the above primary cell cultures and derivative allografts will be 
probed for pVhl and HIF pathway function in order to define the HIF target gene 
repertoire associated with Type 2B Vhl expression compared with wild-type or 
null Vhl alleles.  Primary cell cultures will be used to compare basal and hypoxia-
stimulated levels of HIF-1α and HIF-2α and examine basal and hypoxia-
stimulated HIF transcriptional effects on both conventional and putative Type 2B 
Vhl-associated HIF targets genes.  We will then attempt to define a Type 2B Vhl 
gene expression profile using comparative gene expression profile analysis on 
both primary cell cultures and derivative allografts. 
Our investigations of the representative VHL hotspot mutation R167Q 
suggest that missense Type 2B VHL mutations can confer a more severe 
phenotype than VHL loss.   Coupled with the use of conditional alleles, our 
primary cell culture system will allow us to directly compare the tumor-promoting 
characteristics of the Type 2B Vhl mutation to Vhl loss and Vhl-independent HIF 
stabilization at the molecular level.  
Conclusion 
Altogether, this dissertation work suggests that maximal stabilization of 
both HIF-1α and HIF-2α may create an environment detrimental to some aspects 
of tumor growth.  Instead, a molecular scenario in which HIF-2α is intermediately 
stabilized or stabilized to a greater degree than HIF-1α may be most conducive 
 128 
 
to tumorigenesis.  VHL mutations that generate such a profile of HIF-α 
stabilization, we propose, may cause a more severe clinical course in sporadic 
ccRCC.  Understanding how the levels of HIF-α direct RCC tumor biology will be 
important for determining an individual’s prognosis or likelihood to respond to 
targeted therapy as well as for generating new rational targeting strategies.  
Though targeted therapies against HIF-α are currently under development, our 
work indicates that such therapies may be ineffective or even counter-productive 
if they fail to completely inhibit HIF-α stabilization or activity or if they have 
greater efficacy towards one HIF-α subunit or the other.  Finally and most 
importantly, this dissertation work both encourages ongoing attempts to develop 
genetically engineered mouse models of renal adenocarcinoma and urges further 
study of VHL Disease-associated mutations for insight into the molecular biology 
of both the sporadic and inherited renal cell carcinoma.     
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